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Aryl hydrocarbon receptor (AhR), is a ligand-activated transcription factor that 
integrates environmental, dietary, microbial and metabolic cues to control various cellular 
processes, such as the cell cycle, epithelial barrier function, cell migration and immune 
function. AhR was discovered as the receptor that binds with high affinity to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and leads to numerous of toxicological outcomes. 
In the current study, we discovered a critical role played by AhR, following activation by 
TCDD, in modulating a variety of immunological functions through regulation of 
epigenetic and microbial pathways. Our data demonstrated that AhR activation triggers 
MDSC mobilization from bone marrow to peritoneal cavity which correlated with 
increased levels various of chemokines and their receptors and induced epigenetic 
changes via modulation of small noncoding RNA molecules and targeted genes. These 
MDSCs had high levels of immunosuppressive activity and energy metabolic rate.  Also, 
our data provided a novel link between gut microbiome alterations and MDSC induction 
and function in colon after TCDD administration. Additionally, we provide evidence that 
Resveratrol, a natural polyphenol compound is capable to attenuating the 
immunotoxicological effect of TCDD by altering the migration, differentiation, and 
suppressive function of MDSCs.  Together, our studies demonstrate that AhR can be 
targeted to suppress inflammation and thus treat inflammatory and autoimmune diseases 
as well as cancer. 
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1.1: ARYL HYDROCARBONE RECEPTOR (AhR) 
Aryl hydrocarbon receptor (AHR) is a member of basic helix-loop-helix/Per-
Arnt-Sim (bHLH/PAS) family of transcription factors that need ligand to be activated (1). 
The early studies about AhR were carried out in rat liver and described AhR as enzyme 
induced by foreign chemicals and inducible cytochrome P450 (CYP) monooxygenases 
(2, 3). However, AhR interacts with foreign chemicals (xenobiotics) but also plays a 
critical role in the regulation of immune functions.   Use of Ahr(−/−) knockout mouse 
lines provided strong evidence of the wide importance of AhR in various  critical-life 
processes (4).  
AhR has numerous agonists ncluding xenobiotic such as TCDD, PCDDs, PCB, 
and 3-MC and non-xenobiotic such as Resveratrol, I3C, and l-Kynurenine.  AhR, exists 
as a multiprotein complex, containing three molecules of the chaperone protein hsp90 (a 
heat shock protein of 90 kDa), the X-associated protein 2 (XAP2), and p23 (23-kDa co-
chaperone protein). Following xenobiotic agonist binding, the complex translocates to the 
nucleus and AhR is dimerized with a related nuclear protein called Arnt and converts 
AhR into high affinity DNA binding form. AhR:Arnt complex binds to Dioxin Response 
Element (DRE)  or Xenobiotic Response Elements (XRE) a specific DNA recognition 
site  found on the promoters of various genes, thereby regulating the expression of these 
genes, such as CYP1A1 (5). In addition to XRE and DRE, AhR can also be recruited to 
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novel target DNA sequences by interaction with estrogen receptor, retinoic acid receptor 
(RAR) and retinoblastoma protein (RB) through Krüppel-like factor 6 (KLF6), 
controlling the expression of genes that do not bear XREs in their regulatory regions (6).  
The important role of AhR in regulation of innate and adaptive immunity was 
performed by studies that used AhR knockout mice or mice carrying AhR variants with 
reduced affinity for its ligands (7-9). T helper (TH) cell subsets exhibit differential levels 
of AhR expression. Th17 cells and regulatory T (Treg) cells (including FOXP3
+ 
Treg 
cells and T regulatory type 1 cells (Tr1 cells)) express the highest AhR levels, whereas 
naive CD4
+
 T cells, Th1  and Th2 cells exhibit no or negligible AhR expression (10, 11). 
In DC, AhR may contribute to the anti-inflammatory effects of certain cytokines such as 
TGF-β that increase Treg cell induction (12), or increase FOXP3 Treg generation (13).  
Various studies in last decade have focused on Ahr role in gut specific intestinal 
epithelial cells (IECs). AhR plays important role in IEC regeneration following infectious 






) mice failed to control 
infection by the pathogen Citrobacter rodentium due to impairment of intestinal stem 
cells (ISCs) differentiation into IECs which caused uncontrolled proliferation of these 
cells and increased  malignant epithelial cell transformation (14). In addition, Ahr 
enhances epithelial barrier function and prevent infection through increase in the 
expression of tight junction proteins in response to IL-22 that is produced by DCs and 
CD4
+
 T cells (15, 16), or through controlling the expression of antimicrobial proteins 
such as regenerating islet-derived protein 3β (REG3β) and REG3γ and limiting the 




1.2: MYELOID DERIVED SUPPRESSER CELLS (MDSC) 
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of 
immature and mature myeloid cells exhibiting immunoregulatory activity in both arms of 
immune system, innate and adaptive immunity (18). The major population of bone 
marrow (BM)-derived myeloid cells are granulocytes and mononuclear cells (monocytes, 
terminally differentiated to macrophages and dendritic cells (DCs). In the steady 
condition, macrophage widely expand in situ, while DCs differentiate from their specific 
BM precursors (19). Under physiological conditions, the cell-signaling molecule GM-
CSF drives myelopoiesis. G-CSF induces granulocyte differentiation and M-CSF induces 
macrophage differentiation (20). In chronic inflammation and cancer, these cell-signaling 
molecules are enhanced  and induce MDSCs generation and expansion (21).       





Ly6Chi cells with low side scatter, and Granulocytic (G-MDSCs) or 







with high side scatter (22). M-MDSCs have more suppressive function than PMN-
MDSCs (23). Both of these phenotypes use different mechanism for suppression, The 
most distinct factors involved in MDSC suppressive activity include ARG1, ARG2, NO, 
upregulation of ROS (23-25). A recent study showed inhibition of fatty acid-β oxidation 
(FAO) used by tumor-infiltrating MDSCs as a primary source of energy, impaired the 
suppressive function of tumor-infiltrating MDSCs thereby leading to enhanced the 
immune response against cancer (26).   
It has been reported that there are two groups of interconnected signals involved 
in MDSCs accumulation and activation. First group of signals is responsible for 
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immature myeloid cell expansion whereas, the second group of signal is responsible for 
their activation and promotion of pathologic activity (27). First group includes GM-CSF, 
M-CSF, G-CSF, IL-6, VEGF and polyunsaturated fatty acids and signals primarily via 
STAT3 and STAT5. However this signaling alone is not sufficient without second 
activating signal which is mainly provided by pro-inflammatory molecules such as 
interferon-γ (IFN-γ), IL-1β, IL-4, IL-6, IL-13, tumor necrosis factor (TNF), TLR ligand, 
and signals that utilize NF-κB, STAT1, and STAT6 transcription factors for their 
activation (27-29).  
Numerous studies have been addressed that the proliferation, development, 
migration and function of MDSCs are controlled by epigenetic mechanisms such as DNA 
methylation which enhanced promoter methylation of DNMT3a and DNMT3b and  
improved ARG1 and STAT3 expression with THC treatment (30, 31). Histone 
modification, one of the epigenetic mechanisms, specifically histone deacetyltransferases 
(HDACs), including HDAC2 (32) and HDAC11 also plays a role in MDSC induction 
(33). In physiological conditions, miRNA regulate genes expression that is implicated in 
cell development and differentiation. Several miRNA have been reported that modify 
gene expression and enhance the suppressive function of MDSCs including miR-210, 
miR-494, miR-155, miR-21, and miR-34a  (34-37).  
1.3: 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a typical epitome for a group of 
environmental halogenated aromatic hydrocarbon contaminants which elicit immune 
toxicity and other toxic responses through activation of aryl hydrocarbon receptor (AhR). 
TCDD is infused into the environment by many sources including chemical industries 
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and burning processes. It is considered a byproduct of fossil fuels and wood combustion. 
Also, it is one of the manufacturing remnants of chlorinated hydrocarbons, paper, pulp 
bleaching (38).  International Agency for Research on Cancer, WHO and  US National 
Toxicology Program classified TCDD as human carcinogen (39). TCDD is similar to 
other chlorinated compounds and has bioaccumulation feature in food chain which causes 
food contamination. Ingestion the contaminated food is the most known way to TCDD 
exposure (40). 
 Thymic atrophy is the hallmark of TCDD-mediated immunotoxicity in different 














 thymocytes,  
these shifts in thymocyte subset frequencies was accompanied by a significant decrease 
in the absolute number of thymocytes in each of the four subpopulations (41-44).  It was 
noted recently that thymic atrophy is also caused by activation Ahr in CD11c
+
 dendritic 
cells which may be responsible for TCDD-induced alterations in the development and 
differentiation of thymocytes (45). TCDD also suppresses the activation and 
differentiation of human B cells into Immunoglobulin-M (IgM) secreting cells (46, 47). 
Activation AhR by its high affinity ligand TCDD in CD4
+
 T cells directly alters 
gene expression and increases IL-10 producing and eventually T-cell differentiation to   
FoxP3
– 
type 1 regulatory T cells (Tr1 cells) (48). TCDD through AhR activation, induces 
FoxP3
+
 Treg which promote tolerogenic phenotype and suppress  several immune-
mediated diseases (13, 49-51).  
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In humans, ingestion of contaminated food is one of the most common source of 
TCDD exposure route (40). The gastrointestinal tract is the largest habitat of microbiota. 
The diversity of microbes within a given host can be defined as the number and 
abundance of distribution of distinct types of organisms such as bacteria, archaea, 
protists, fungi and viruses, which have been linked to immunologic, hormonal, and 
metabolic homeostasis of their host. Microbiome dysbiosis occurs due to a wide range of 
causes such as diseases, environmental contamination, diet, and stress (52-54). Emerging 
studies reported that TCDD after exposure is rapidly absorbed from the gastrointestinal 
and causing shift in gut commensals (55, 56). 
1.4: 3,5,4'-TRIHYDROXYSTILBENE (RESVERATROL) 
Resveratrol (RSV) is a natural polyphenolic products that is synthesized as a 
phytoalexin (compounds that are produced in plants as a defense mechanism  against 
pathogenic and stressful environmental situations) in plants such as grapes, soy, nuts, and 
chocolate (57). The chemical structure of resveratrol (trans-3,5,4′-trihydroxystilbene) is 
identified in two isomeric forms, cis- and trans-resveratrol, both of isomeric forms have 
different biological activities (58). Because of anti-inflammatory, antioxidant, 
antibacterial, and anticancer properties of resveratrol, it has received recently significant 
scientific attention. 
Plurality of anti-inflammatory features of RSV have been investigated widely in 
inflammatory bowel diseases, when  5-20 mg/kg of RSV doses reduced colitis symptoms 
by decreasing the production of inflammatory cytokines IL-1β, IL-12, IL-6, TNF-α, 
COX2, and prostaglandin D2 (PGD2) and increased the levels of IL-10 in rat colitis 
models (59-61). Numerous studies from our lab  showed the protective role of RSV in 
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various inflammatory disease including lung injury (62, 63), kidney injury (64), liver 
injury (65), and colitis (66, 67). Also, RSV showed a marked protective effect on 
inflammatory and autoimmune disease such as allergic asthma (68), and multiple 
sclerosis (69).  
In terms of its antioxidant capability,  RSV has an aromatic ring structure and OH 
group that provides electrons which help to scavenge free radicals that are generated in 
the electron transport chain undergoing oxygen-consuming reaction (70). RSV protects 
hippocampal neuron from ROS by its scavenging properties (71).  Interestingly, RSV 
inhibits QR2, a cytosolic enzyme which enhances the production of damaging ROS and 
involved in memory impairment.  Inhibition of QR2 reduced hippocampal neuronal cell 
death– a brain area involved in learning and memory, in the rat model (72).  
 RSV is considered antibacterial because it is a molecule that has ability to 
interact with more than 20 proteins in eukaryotic organisms including Mycobacterium 
smegmatis and  Escherichia coli, the interaction is accompanied with inhibition of both 
ATP hydrolysis and ATP synthesis functions which stop bacterial growth in media (73-
75).  
RSV was reported to exert multiple anticancer activity in various cancer cell lines 
through varied mechanisms.  Treatment with resveratrol induced apoptotic cell death by 
increasing ROS in the human ovarian cancer cell lines, A2780 and SKOV3 (76). In 
gastric cancer cell line BGC823, RSV 200 µM inhibited the viability, migration, and 
invasion of cells and suppressed metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) expression, which was overexpressed in gastric cancer cells (77). 
Furthermore, RSV inhibited the Interleukin-6 induced SGC7901 cell invasion and matrix 
8 
 
metalloproteinase activation through inhibition of Raf/MAPK pathway of activation (78).  
RSV inhibited lung cancer tumor growth that was induced by injection of LLC tumor 
cells in B6 mice through reduction of F4/80
+
 expressing cells and M2 polarization in 
tumors (79). Studies from our lab have shown that RSV reduced colitis and prevented 
colon cancer through modulation of CD3(+) T cells that express tumor necrosis factor-alpha and 
IFN-gamma or through the up-regulation of SIRT-1 in immune cells in the colon (80, 81).  
Studies from our lab have also shown that RSV can serve as a ligand or agonist of AhR, 
based on the dose  (82)   
Hypothesis:  In the current study, we tested the central hypothesis that activation 
of AhR by TCDD may induce significant alterations in the activation and migration of 
MDSCs and that this effect may result from modulation of gut microbiota.  Interestingly, 
we noted that TCDD induced massive mobilization of MDSCs and MDSC subsets from 
bone marrow to peritoneal cavity which was regulated by the miRNA. Also, we found 
that TCDD caused gut microbiome dysbiosis, which also played a crucial role in the 
induction of MDSCs.  Furthermore, we also observed that RSV attenuated 
immunomodulating properties of TCDD by reducing the mobilization, differentiation, 







AHR ACTIVATION LEADS TO MASSIVE MOBILIZATION OF MYELOID 
DERIVED SUPPERSSOR CELLS (MDSCS) WITH IMMUNOSUPPRESSIVE 
ACTIVITY THROUGH REGULATION OF CXCR2 AND MIR-150-5P AND MIR-
543-3P THAT TARGET ANTI-INFLAMMATORY GENES 
 
2.1 ABSTRACT 
TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), an environmental contaminant, is a 
potent ligand for Aryl hydrocarbon receptor (AhR). In the current study, we made an 
exciting observation that naïve C57BL6 mice exposed intraperitoneally to TCDD showed 
massive mobilization of MDSCs in the peritoneal cavity. These MDSCs were highly 
immunosuppressive and attenuated Con-A-induced hepatitis upon adoptive transfer.  
TCDD administration in naïve mice also led to induction of several chemokines and 
cytokines in the peritoneal cavity and serum (CCL2, CCL3, CCL4, CCL11, CXCL1, 
CXCL2, CXCL5, CXCL9, G-CSF, GM-CSF, VEGF and M-CSF), and chemokine 
receptors on MDSCs (CCR1, CCR5, and CXCR2).  Treatment with CXCR2 or AhR 
antagonists in mice led to marked reduction in TCDD-induced MDSCs. TCDD-induced 
MDSCs had high mitochondrial respiration, glycolytic and ATP rates and exhibited 
differential miRNA expression profile.  Specifically, there was significant down-
regulation of miR-150-5p and miR-543-3p. These two miRNAs targeted and enhanced 
anti-inflammatory genes, including IL-10, PIM1, ARG2, and STAT3 as well as CCL11 
and its receptors CCR3 and CCR5 as wells as CXCR2. The role of miRs in MDSC 
activation was confirmed by transfection studies. Together, the current study 
10 
 
demonstrates for the first time that activation of AhR in naïve mice triggers robust 
mobilization of MDSCs through induction of chemokines and their receptors, and MDSC 
activation through regulation of miRNA expression.  AhR ligands include diverse 
compounds from environmental toxicants such as TCDD that are carcinogenic to dietary 
indoles that are anti-inflammatory.  Our studies provide new insights on how such ligands 
may regulate health and disease through induction of MDSCs.   
2.2 INTRODUCTION 
 TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin) is a halogenated aromatic 
hydrocarbon found in the environment as a contaminant with immunotoxic and 
carcinogenic properties. It is well characterized for its ability to act as a high affinity 
ligand for AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) 
family of transcription factors. In fact, AhR is required for induction of toxicity inasmuch 
as mice deficient in AhR are mostly resistant to TCDD-mediated toxicity (83).  More 
recent studies have demonstrated that AhR may also play a crucial role in regulating 
various physiological and developmental processes including the functions of the 
immune system (84).  
 Extensive studies have shown that the immune system is one of most sensitive 
targets of TCDD.  Multiple mechanistic pathways have been identified to delineate how 
AhR activation leads to regulation of the immune system.  These include but not limited 
to: activation of Fas which expresses DREs leading to induction of apoptosis of activated 
T cells (84-87). induction of FoxP3 and Tregs by virtue of the fact that FoxP3 expresses 
DREs on its promoter (88, 89). promoting Tregs while suppressing Th17 cells through 
decreased methylation of CpG islands of Foxp3 and increased methylation of IL-17 
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promoter (50, 85) differential miRNA induction such as decreased expression of miR-31, 
miR-219, and miR-490 that targeted Foxp3, and increased expression of miR-495 and 
miR-1192 that were specific to IL-17 (90). AhR ligands also include dietary compounds 
such as indole-3-carbinol (I3C),3,3’-diindolylmethane (DIM), and resveratrol (37, 82, 91-
93). The essential amino acid tryptophan, acquired from the diet, also serves as a source 
of AhR ligands (94). It is interesting to note that while some AhR ligands are considered 
to be highly toxic and carcinogenic, others constitute ligands that are endogenously 
produced or found in the diet that regulate immune response in health and disease.   Also, 
while some AhR ligands such as TCDD are known to trigger Tregs, others such as 6-
formyl indolo[3,2-b]carbazole (FICZ), induce Th17 cells (89, 90). Thus, the precise 
mechanisms through which AhR ligands regulate the immune response needs further 
investigation.    
 Myeloid-Derived Suppressor cells (MDSCs) are heterogeneous populations 
derived from bone marrow and comprised of myeloid progenitors that under normal 
conditions, differentiate into dendritic cells, granulocytes, and macrophages (95). In 
situations involving chronic infection, inflammation, trauma or malignancy, the 
associated chemokines and cytokines induce abnormal accumulation of such immature 





 surface markers (97, 98). MDSCs have contradictory roles in infection 
and immunity. They may act as a double-edged sword during the early and late stages of 
infection and inflammation, from promoting innate immunity in early stages to 
attenuating the immune system through inducing immunosuppressive conditions in late 
stages of infection (99). In some cases, increasing MDSCs during infection help to reduce 
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inflammatory extension and limit undesirable tissue damages (100). In cancers, MDSC 
accumulation can prevent anti-cancer immunity thereby facilitating the tumor growth. 
MDSCs have also been shown to induce Tregs and regulate macrophage (101, 102).  
2.3 MATERIALS AND METHODS        
Experimental Animals:  
Female mice C57BL/6 mice (6-8) weeks old were purchased from Jackson 
laboratory, USA. All mice were housed in specific pathogen-free condition at the 
AAALAC-accredited University of South Carolina, School of Medicine, Animal 
Resource Facility. All experiments performed using mice were approved by the 
Institutional Animal Care and Use Committee (IACUC), University of South Carolina.   
Chemicals and reagents 
TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences & 
Technology, Texas A&M Health Sciences Center, College Station, Texas). RSV was 
purchased from Supelco (MO, USA). Concanavalin A (Con A), N acetyl-cysteine (NAC), 
AhR antagonist (CH223191) and CXR2 antagonist (Sch527123) were purchased from 
Sigma-Aldrich, N.C. Culture medium reagents (RPMI 1640, Penicillin-Streptomycin, 
HEPES, L-Glutamine, FBS, and PBS) were purchased from Invitrogen Life Technologies 
(Carlsbad, CA). The following antibodies were used for surface markers, and/or intra-
nuclear staining and were purchased from BioLegend (San Diego, CA-USA): FITC or 
Alexa Fluor 700-conjugated anti-CD11b, PE or BV510-conjugated-GR-1, Alexa Fluor 
488-conjugated anti-Ly6C, BV785-conjugated anti-Ly6G, PE or BV785-conjugated anti-
CD4, PE-conjugated anti-CD3, and BV510-conjugated anti-NrP1. PE-conjugated anti-IL-
17, BV605-conjugated anti-IL-10, BV650-conjugated anti-INF-g, PerCP-Cy™5.5-
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conjugated anti-TGF-β, and Alexa Flour 488-conjugated anti-IL-4, Alexa Fluor 488-
conjugated anti-FOXP3 and PE-Dazzle-conjugated anti-Helios. Fc Blocker reagent was 
procured from BD Biosciences (San Diego, USA). Monoclonal Mouse IgG anti Arg1 
were purchased from BD Biosciences (San Diego, USA). Monoclonal Rat IgG antibodies 
of CD11b and Ly6G/Ly6C (GR-1) were purchased from R&D Systems Biotech Brand 
(Minneapolis, USA). Cytofix/CytopermTM Fixation/ Permeabilization kit was purchased 
from BD Biosciences (San Diego, USA). True-Nuclear™ Transcription Factor Buffer Set 
was from BioLegend. EasySep™ PE Positive Selection Kits were purchased from Stem 
cells Technologies (Vancouver, BC, Canada). RNeasy and miRNANeasy Mini kits, 
miScript primer assays kit, and miScript SYBR Green PCR kit were obtained from 
QIAGEN (QIAGEN, Valencia, CA). The following reagents: iScript and miScript cDNA 
synthesis kits were purchased from Bio-Rad (Madison, WI). Epicentre’s PCR premix F 
and Platinum Taq DNA Polymerase kits from Invitrogen Life Technologies (Carlsbad, 
CA). ELISA kits for IL-4, IL-10 and TGF-b (ELISA MAXTM Standard SET Mouse) 
were bought from BioLegend. XFp glycolytic rate assay kit and XFP cell mito stress test 
kit were purchased from Agilent Technologies. 
 Induction of MDSCs in mice by TCDD.  
Groups of 5 mice were injected intraperitoneally (i.p.) with TCDD (1-10µg/kg) or 
the vehicle, corn oil. At various days post exposure, mice were euthanized, peritoneal 
cells were collected, and washed twice with PBS. The cells were counted and stained for 
MDSC markers (CD11b and Gr-1), Granulocytic MDSCs (G-MDSCs: CD11b and Ly6-
G), and Monocytic MDSCs (M-MDSCs: CD11b and Ly6-C) populations by flow 
cytometry (BD FACScelesta), as described (103).  Feces were collected from two groups 
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as well as from naïve group and kept in -80 0C for later use. For RSV treatment, mice 
were given orally 50 mg/kg RSV prior one day from TCDD 10 µg/kg injection, upon one 
day of TCDD exposure, cells from peritoneal cavity were collected and stain with 
MDSCs and MDSCs subset phenotype markers.  
Purification of MDSCs and their subsets M-MDSCs and G-MDSCs 
TCDD-induced MDSCs were purified from exudates of peritoneal cavity, as 
described previously (31). In brief, peritoneal exudates were collected from TCDD-
exposed mice and labeled with PE-conjugated Gr-1 antibody. PE-selection kit from Stem 
Cells Technologies was used for selection and following the protocol from company. 
After purification, flow cytometry (BD FACScelesta) was used to assess the purity of 
MDSCs. We purified M-MDSCs and G-MDSCs subsets of MDSCs using FACS Aria II 
sorter (BD FACS Aria II). Peritoneal exudate cells were stained with CD11b and LY6C 
for M-MDSCs or CD11b and LY6G for G-MDSCs. 
 AhR and CXCR2 antagonists  
Mice were injected i.p with 10 mg/kg or 50 mg/kg of AhR antagonist 
(CH223191) or CXCR2 antagonist (Sch527123) respectively, one day before TCDD 
injection. Peritoneal exudates were collected in day 3 and stained with CD11b, Gr-1, 
LY6G and LY6C to detect MDSCs and subset of MDSCs.  
 Effect of TCDD-induced MDSCs and MDSCs subsets (M-MDSCs and G-MDSCs) 
on T-cell proliferation in vitro   
To examine the suppressive effect of MDSCs on T-cell proliferation, splenocytes 
(5x10
5
) from C57BL/6 naïve mice were cultured in the presence of Con-A (2µg/ml) 
together with different ratios of TCDD-generated MDSCs, M-MDSCs and G-MDCSs for 
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24 hrs, as described (104). [3H]thymidine (1µCi/well) was added to the cells cultures and 
after 18 hrs, radioactivity was measured using a liquid-scintillation counter (MicroBeta 
Trilux; PerkinElmer Life and Analytical Sciences).  
Mitochondrial respiration, glycolytic rate, and ATP rate.    
Oxygen consumption rates (OCR), proton efflux rate (PER), and ATP rate were 
measured in 2×10
5
 of purified MDSCs from peritoneum of vehicle or TCDD-treated mice 
using XF Extracellular Flux Analyzer (Seahorse Bioscience). For OCR, MDSCs were 
plated in XF cell culture plate coated with 15 μg CellTak (BD Biosciences) in XF assay 
medium supplied with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose. MDSCs 
were analyzed under stressed conditions and in response to 1 μM oligomycin, 1 μM 
fluorocarbonyl-cyanide-phenylhydrazone (FCCP), and 0.5 μM rotenone and antimycin-
A. For PER, MDSCs were plated in XF cell culture plate coated with 15 μg CellTak in 
phenol red-free Base Medium enriched with 2 mM glutamine, 10 mM glucose, 1 mM 
pyruvate, and 5 mM HEPES as initial conditions. Cells monitored under stressed 
conditions and in response to 0.5 µM Rotenone plus Antimycin A (Rot/AA) and 50 mM 
2-Deoxy-D-glucose (2-DG). For ATP rate, MDSCs were plated in XF cells culture plate 
with 15 μg CellTak in DMEM Medium enriched with10 mM of glucose, 1 mM of 
pyruvate, 2 mM of glutamine. ATP rate production measured under stressed conditions in 
response to 1.5 µM of oligomycin and 0.5 µM Rotenone + Antimycin A.  All three tests 
quantified by Seahorse Bioscience XFp Extracellular Flux Analyzer (Agilent 





Proliferation assessment by BrdU and Ki67 labeling in vivo 
To characterize MDSCs proliferation in vivo, mice were injected with BrdU (100 
mg/kg) two hours before TCDD treatment, as described (105, 106). Cells from the 
peritoneal exudate were harvested and were first stained using anti-mouse antibodies 
against CD11b and Gr-1. After fixation and permeabilization, the cells were stained with 
PerCP-Cy™5.5-conjugated anti-BrdU (BD Biosciences) and PE-conjugated anti-Ki67 
antibodies (Biolegend) and using intranuclear staining protocol (BD Biosciences). Quad-
stained cells were analyzed by flow cytometry (BD FACScelesta). 
Con-A-induced hepatitis and adoptive transfer of MDSCs 
To generate hepatic inflammation, (C57BL/6) mice were injected intravenously 
(iv) with Con-A (12.5mg/kg) as described (103).  For adoptive transfer, Con-A injected 
mice received 5 million purified MDSCs from peritoneal cavity (PC-MDSCs) or bone 
marrow MDSCs (BM-MDSCs) from TCDD-treated mice 1 hr before Con-A injection. In 
experiments where TCDD was tested for its ability to attenuate ConA-induced hepatitis, 
mice received TCDD (10 µg/kg) by i.p. route, 1 hr before ConA injection. Mice were 
sacrificed after 48 hrs post treatment and spleens and livers were harvested as well as 
blood was collected.  Single cell suspension of splenocytes was prepared and infiltrating 
mononuclear cells in the liver were isolated using Percoll gradient, as described (107). 
Harvested cells from spleens and liver mononuclear were stained with Abs against CD4 
and INF-ƴ or IL-17 or IL-4 or IL-10 to determine Th1, Th-17, Th-2 and induced T-reg 
cell populations by flow cytometry (Beckman Coulter). IL-4 and TGF-b cytokines level 




Enzyme-linked immunosorbent assay (ELISA) 
 Serum from individual mouse was collected and the concentration of various 
cytokines including, IL-4, and TGF-β was measured using ELISA MAXTM Standard 
SET Mouse kit for respective cytokines were purchased from Biolegend. 
Chemokines analysis 
Serum and peritoneal exudates were collected from individual mouse after 3 days 
of TCDD or vehicle injection. G-CSF, GM-CSF, M-CSF, Eotaxin (CCL11), LIF, LIX 
(CXCL5), KC (CXCL1), MCP-1 (CCL2), MIP-1A (CCL3), MIP-1B (CCL4), MIP-2 
(CXCL2), MIG (CXCL9), RANTES (CCL5), and VEGF concentrations were determined 
by using Milliplex map kit (Sigma-Milipore, USA)  according to the manufacturer 
protocol and analyzed by Bio-Plex chemiluminescence assay system (Bio-Rad). 
Histopathology of liver  
Livers were harvested from mice and fixed in formaldehyde (4%) overnight, then 
embedded in paraffin and cut to ~6 micron-thickness. The liver sections were then 
stained with hematoxylin and eosin (H&E) and analyzed by Cytation5 microscopic 
system (BioTek, USA). 
 microRNA Arrays and Analysis 
miRNA analysis was carried out as describe (31). Total RNA including 
microRNA was isolated from peritoneal MDSCs post-TCDD administration using 
miRNAN easy kit from Qiagen and following the protocol of the company (Qiagen). 
miRNAs arrays were performed using Affymetrix miRNA array (version 4). Signal 
expression (fold change) of more than 3000 miRNAs were detected from the raw array 
data and only those miRNAs that were altered more than 2-fold, were considered for 
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further analysis. The selected miRNAs were further analyzed for their targets and 
alignments using TargetScan, microRNA.org, and miRNAWalk database. Furthermore, 
selected miRNAs were analyzed for their role in various diseases and pathways using 
Ingenuity pathway analysis (IPA) software. miRNAs from various groups were also 
analyzed for their relationship using LucidChart or Venn Diagram. 
 Real-Time (Q-PCR) to validate miRNAs and associated genes expression  
Q-PCRs were performed to determine the expression of selected miRNAs 
(miRNA-150-5p, and miRNA-543-3p) on cDNAs synthesized from total RNAs including 
miRNAs isolated from peritoneal MDSCs post-TCDD or vehicle exposure. miScript 
primer assays kit (QIAGEN, Valencia, CA) and SSo advance SYBR Green PCR kit from 
Bio-Rad,were used and Q-PCR was performed following the protocol of the company. 
For Q-PCR run conditions to detect miRNA: 15min at 95°C (initial activation step), 
followed by 40 cycles of 15s at 94°C (denaturing temperature), 30s at 60°C (annealing 
temperature), and 30s at 70°C (extension temperature and fluorescence data collection) 
were used.  Normalized expression (NE) of miRNAs was calculated using NE ¼ 
2_DDCt, where Ct is the threshold cycle to detect fluorescence. The data were 
normalized to miRNAs against internal control miRNA (SNORD96A, Qiagen-Germany) 
and fold change of miRNAs was calculated against control miRNA (SNORD96A) and 
treatment group (TCDD) was compared with vehicle group.  
Real time PCR (RT-PCR) to determine the expression of IL-10, ARG2, STAT3, 
INOS1 and PIM1 in MDSCs post-TCDD or vehicle treatment. 
RT-PCR was performed to detect IL-10, ARG2, STAT3, PIM1, CCL11, CCR1, 
CCR3, CCR5, and CXCR2 expression. Primers of these genes are specifically designed 
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to above genes through IDT tools (Table 2.1). RT-PCR was performed for 40 cycles 
using the following conditions: at 98°C (denaturing temperature) for 30 s, at 98°C 
(annealing temperature) for 10 s, and at 60°C (extension temperature) for 30 s.  The PCR 
products, generated from mouse gene-specific primer pairs, were visualized with UV 
light performing electrophoresis (1.2% agarose gel). The band intensity of PCR products 
was determined using ChemiDoc image analysis system from Bio-Rad (Bio-Rad, 
Hercules, CA). The expression of the above genes were normalized against PCR products 
generated from mouse housekeeping gene GAPDH (internal control).  
Statistical analysis. 
  GraphPad Prism software version 6.01 (San Diego, CA) was used for statistical 
analysis. A standard t-test or multiple t-test with Holm-Sidak’s multiple comparisons 
corrections was used when comparing two groups for significance.  A one-way or two-
way analysis of variance (ANOVA) with post hoc Tukey’s multiple comparisons test was 
used to compare between the means of more than two groups. Error bars were expressed 
as Mean ± standard error of mean (±SEM), and significance was determined as having a 
p value less than 0.05. Each experiment was repeated at least twice with consistent 
results. 
2.4 RESULTS 
TCDD induces MDSCs in mice. 
TCDD is a potent agonist of AhR and thus, we used TCDD to test if activation of 
AhR leads to induction of MDSCs.  To this end, three doses of TCDD (1, 5, and 10 µg/kg 
body weight) or vehicle were injected (i.p.) into C57BL/6 mice and peritoneal exudates 
collected on day 3 post treatment. The presence of MDSCs in peritoneal cavity was 
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analyzed by staining the cells with fluorophore labeled anti-mouse CD11b and Gr-1 
antibodies and using flow cytometry. There was a dose-dependent increase in both the 




 cells in peritoneal cavity (Fig 2.1A-B) of mice 
that received TCDD, when compared to mice that received vehicle.  Upon analysis of 
subsets of MDSCs (monocytic and granulocytic) by staining the cells with Abs against 














TCDD treatment, when compared to vehicle controls (Fig 2.1C-D).  However, the 
granulocytic MDSCs were significantly more in both the percentages and total numbers 
when compared to monocytic MDSCs.  To study the time course, we injected mice with 
TCDD and collected peritoneal exudates on days 1, 2 and day 3 post-treatment. We 
observed significant induction of MDSCs on day 1 and their numbers continued to rise 
till day 3 (Fig 2.1E-F). Additionally, on day 3, we noted that the proportion of G-MDSC 
induction was significantly more than that of M-MDSCs (Fig 2.1G-H). Together, these 
data demonstrated that TCDD induces robust MDSCs in the peritoneal cavity.   
 TCDD induces MDSCs through activation of AhR   
Because TCDD is a potent ligand for AhR, we tested the effect of AhR antagonist 
(CH223191) on the induction of MDSCs by TCDD. We found administration of AhR 
antagonist significantly reduced the number of MDSCs (Fig 2.2A-B) and MDSC subsets 
(Fig 2.2C-D), thereby suggesting that TCDD was inducing the MDSCs, at least in part, 





TCDD promotes the migration of MDSCs from bone marrow to peritoneal cavity 
through chemokines induction. 




 while their 
proportion is much smaller in the spleens (2–4%), and they are absent in the lymph nodes 
(95). Thus, we next determined if TCDD was promoting the migration of MDSCs from 




 cells in bone marrow and 
peritoneal exudate at 0 hr and 16 hrs post-TCDD treatment, by flow cytometry 





 cells in bone marrow after 16 hrs following TCDD treatment while there 





 cells from the bone marrow may be migrating to the 
peritoneal cavity, the site of TCDD administration.  Next, we investigated if specific 
chemokines have a role to recruit MDSCs from bone marrow to peritoneal cavity.  To 
that end, we detected some chemokines and cytokines that regulate MDSCs, and found 
that the peritoneal fluid of TCDD-injected mice had significant levels of MCP-1 (CCL2), 
MIP-1A (CCL3), MIP-1B (CCL4), Eotaxin (CCL11), KC (CXCL1), MIP-2 (CXCL2), 
MIG (CXCL9), VEGF, and M-CSF when compared to controls.  Also, we saw an 
increase in CCL2, CCL4, CXCL1, CXCL5, G-CSF and GM-CSF in the serum of TCDD-
treated mice (Fig 2.3C-D). We also assessed chemokines receptors expression in MDSCs 
post-TCDD treatment. We found that three of the chemokine receptors increased in 
TCDD-induced MDSCs group (CCR1, CCR5, and CXCR2) when compared to vehicle-
induced MDSCs group (Fig 2.3E).  Next, we investigated if blocking CXCR2 would have 
an effect on MDSCs recruitment to peritoneal cavity. To this end, we injected CXCR2 
22 
 
antagonist Sch527123 in mice one day before TCDD treatment and after 3 days, MDSCs 
were assessed in peritoneal cavity.  We observed that MDSC percentage and numbers 
were dramatically decreased following CXCR2 antagonist treatment when compared to 
controls (Fig 2.3F). We also examined whether TCDD induces only the migration of 
MDSCs from bone marrow to peritoneal cavity or it also induces MDSCs proliferation in 
the peritoneal cavity.  To that end, we injected BrdU in mice 2 hrs before TCDD 
treatment. After 48 hrs, we stained the peritoneal cells using fluorophore labeled anti-
mouse CD11b and Gr-1 antibodies as well as intranuclear BrdU, and intracellular Ki67. 
We observed no significant difference in BrdU and Ki67 positive cells between vehicle 
and TCDD groups demonstrating that TCDD does not induce proliferation of MDSCs in 
the periphery (Fig 2.3G).   
TCDD-induced peritoneal MDSCs, M-MDSCs, and G-MDSCs mediate suppression 
of T cell activation in vitro 
Immune suppression is the hall mark feature of MDSCs and thus, to determine if 
TCDD-induced MDSCs can suppress T cell activation, we performed T cell proliferation 
assays using ConA (2 µg/ml) in the presence or absence of TCDD-induced MDSCs 
collected from peritoneal cavity. We observed dose-dependent suppression of T cell 
activation in the presence of MDSCs and furthermore, while both G-MDSC and M-
MDSCs were suppressive, the latter were found to be more effective (Fig 2.4A-C). 
TCDD-induced peritoneal MDSCs have high mitochondrial respiration, glycolytic 
and ATP rates. 
Tumor-infiltrating MDSCs (T-MDSCs) have been shown to have increased 
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), when 
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compared to splenic-MDSCs (29). To explore the nature of TCDD-induced MDSCs, we 
tested the Oxygen Consumption Rate (OCR) and Proton Efflux Rate (PER) as well as 
ATP rate using Seahorse Bioscience XFp Extracellular Flux Analyzer. We observed that 
TCDD-induced MDSCs from peritoneal cavity had higher OCR, PER and ATP 
production rate in comparison to vehicle- induced MDSCs (Fig 2.4D-F). 
TCDD-induced MDSCs protect ConA-induced liver damage in vivo.  
Next, we investigated whether TCDD-induced MDSCs are functional in vivo in 
suppressing T cell response.  We have shown earlier that MDSCs can protect liver from 
ConA-mediated hepatitis in vivo (108). To that end, we injected naïve mice with purified 
TCDD-induced MDSCs from peritoneal cavity or bone marrow, i.v. followed 1 hr later 
with ConA.  Spleens and livers of mice treated with peritoneal-MDSCs or BM-MDSCs 
were harvested 48 hrs after treatment. Upon histological analysis of liver, there was 
reduced liver inflammation in mice that received TCDD-peritoneal-MDSCs, when 
compared to mice that received MDSCs from BM (Fig 2.5A). Analysis of alanine 
transaminase (ALT) in sera showed significantly reduced ALT level in sera of mice that 
received TCDD-peritoneal MDSCs, when compared to mice that received MDSCs from 
BM (Fig 2.5B). Moreover, levels of IL-4 and TGF-β (anti-inflammatory cytokines) 
increased in sera of mice that received TCDD-peritoneal-MDSCs, when compared to 
mice that received BM-MDSCs (Fig 2.5C). These data suggested that TCDD-induced 
peritoneal MDSCs are more immunosuppressive in function in vivo, when compared to 




TCDD-induced MDSCs reduce inflammation in liver and spleen of ConA induced 
hepatitis mice.  
To better understand the suppressive effect of TCDD-induced peritoneal MDSCs, 
we purified mononuclear cells from livers as well as spleen cells from mice treated with 
peritoneal-MDSCs and BM-MDSCs as described in Materials and Methods. The 
mononuclear cells and splenocytes were stained to determine Th1, Th17, Th2 and 









 in the spleens of mice treated with TCDD-induced peritoneal MDSCs, when 









 in the spleens of mice treated 
with peritoneal-MDSCs, when compared to cells from mice treated with BM-MDSCs 
(Fig 2.5D-E)  
TCDD reduces inflammation in ConA-induced hepatitis in mice by generating 
MDSCs and Tregs. 
To test if TCDD would directly suppress ConA-induced hepatitis and if this is 
regulated by MDSCs, we injected mice with TCDD (10µg/kg) or vehicle 1 hr before 
ConA (10mg/kg) injection (iv). We noted that TCDD was able to decrease ALT levels 
thereby showing protection of liver damage (Fig 2.6A). Next, we stained the spleen cells 
and liver mononuclear cells for MDSCs, various T helper cells (Th1, Th2, and Th3), and 
Treg subsets (tTreg, pTreg, and Tr1). We observed significant increase in MDSCs and G-
MDSCs in spleens of mice exposed to TCDD, when compared to mice treated with 





 cells and Th1 cells and an increase in the percentages of Th2 cells in TCDD-
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treated mice when compared to vehicle-treated mice (Fig 2.6D-G). For Treg and its 





population (Fig 2.6I) and in the percentages of pTregs, and Tr1, as well as in the 
percentage of Th3 cells in spleen of TCDD-treated mice in comparison to vehicle-treated 




 (Fig 2.6J) and tTregs (Fig 
2.6K) were significantly decreased in mice were treated with TCDD, when compared to 
mice treated with vehicle. 
TCDD altered miRNAs expression in peritoneal MDSCs.  
Our previous studies demonstrated that miRNA play a critical role in MDSC 
induction (65). To that end, we investigated the role of miRNA in the induction of 
MDSCs by TCDD, by performing miRNA microarray using MDSCs derived from 
vehicle or TCDD-treated groups.  There were more than 3195 miRNAs that were 
analyzed by arrays (Fig 2.7A) of which the expression of only 141 miRNAs were altered 
by greater than two-fold in TCDD-treated groups when compared to vehicle-controls (Fig 
2.7A).  As shown in Venn diagram, there were 3054 miRNAs that showed no change 
(Fig 2.7B), while 97 miRNAs were upregulated, and 44 miRNAs were downregulated 
(Fig. 2.7B). Figure 2.7C depicts upregulated (n=97) and downregulated (n=44) miRNAs 
in TCDD-induced MDSCs, when compared to vehicle-induced MDSCs. Similarly, Fig 
2.7D depicts TCDD-dysregulated (upregulated and downregulated) miRNAs in TCDD-
induced peritoneal MDSCs. Furthermore, upon analysis of 141 dysregulated miRNAs 
using ingenuity pathway analysis (IPA) software, we observed a direct relationship 
between various miRNAs and the target genes including miR-150-5p and the target genes 
IL-10 and PIM1, and miR-543-3p and the target genes ARG2 and STAT3 as well as 
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CCL11, CCR3, CCR5 and CXCR2 (Fig 2.7E). These data suggested that TCDD-
mediated alterations in the miRNAs may regulate the expression of various target 
molecules such as IL-10, PIMI, ARG2, STAT3, CCL11, CCR3, CCR5 , and  CXCR2 
that are prominently involved in the induction and functions of MDSCs.       
Real-Time (Q-PCR) to validate selective miRNAs and the target genes. 
Based on the complementary binding affinity of miR-150-5p with IL-10 and PIMI 
genes (Fig 2.8A) and miR-543-3p with ARG2, STAT3, and CXCR2 (Fig 2.8B) as well as 
with CCL11, CCR3, and CCR5 (Fig 2.8C), we selected miR-150-5p and miR-543-3p to 
validate their expression. Q-PCR data showed significant downregulation of both miR-
150-5p and miR-543-3p in TCDD-induced peritoneal MDSCs, when compared to 
vehicle-induced MDSCs (Fig 2.9A). Next, we examined the expression of target genes 
IL-10 and PIM1 (miR-150-5p target genes), ARG2, STAT3, CCL11, and CCR5 (miR-
154-3p target genes) by performing Q-PCR. We observed significant upregulation all 
these genes in TCDD-induced peritoneal MDSCs, when compared to vehicle-induced-
MDSCs (Fig 2.9B). These data demonstrated that TCDD-alters the expression of miRNA 
in MDSCs which may lead to their induction and functions.   
Analysis of miR-150-5p and miR-543-3p and specific targeted genes expression.  
To further understand the role of miR-150-5p in IL-10 and PIM1 expression and 
miR-543-3p in ARG2, STAT3, CCL11, CCR3, CCR5, and CXCR2 expression, we 
performed a series of transfection assays. To that end, MDSCs were mock-transfected or 
transfected with mature miR-150-5p, mature miR-543-3p, anti-miR-150-5p inhibitor or 
anit-miR-543-3p inhibitor, and cultured for 24hrs. Next, the expression of various 
miRNAs and their target molecules was studied.  Mock-transfected MDSCs showed basal 
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level expression of both miR-150-5p and miR-543-3p. MDSCs transfected with mature 
miR-150-5p and miR-543-3p showed significantly upregulated expression of both 
miRNAs in transfected MDSCs. However, transfection of MDSCs with anti-miR-150-5p 
and ani-miR-543-3p inhibitors showed downregulated expression of both miRNAs in 
MDSCs (Fig 2.9C,E). These data demonstrated that transfection of MDSCs with mature 
miRNAs or anti-miRNAs inhibitors showed expected results. To further understand the 
role of these two miRNAs, we performed q-PCR to determine the expression of IL-10, 
PIM1, STAT3, ARG2, CC11 genes and chemokines receptors CCR2, CCR5, and 
CXCR2.  As shown in Fig 2.9D, the expression of IL-10 and PIM1 was significantly 
reduced in MDSCs in the presence of miR-150-5p. However, the expression of the above 
genes was significantly increased in MDSCs in the presence of anti-miRNA inhibitor. 
Figure 2.9F showed significant reduction in the expression of ARG2, STAT3 as well as 
chemokine CCL11 and chemokines receptors, CCR3, CCR5, and CXCR2 (Fig 2.9G) in 
MDSCs in the presence of miR-543-3p. However, there was a significant increase in the 
expression of these genes and chemokines receptors in the presence of anti-miRNA 
inhibitor.  Together, these data demonstrated that TCDD-mediated alterations in the 
expression of miRNA may play a critical role in MDSC induction and functions.   
2.5 DISCUSSION 
 In the current study we made an exciting observation that TCDD potently 
induces MDSCs at the site of administration even in naïve animals.  Also, TCDD was 
able to induce MDSCs in an inflammatory model of ConA-induced hepatitis.  We found 
that TCDD-induced MDSCs were highly immuosuppressive as demonstrated using in 
















). Additionally, we found that TCDD caused alterations in the 
expression of miRNA in MDSCs that promote the immunosuppressive functions of 
MDSCs.   
TCDD is well characterized for its immunosuppressive properties that are 
mediated through activation of AhR (109-112). TCDD-mediated immunosuppression 
may involve multiple pathways because AhR ligation leads to activation of DREs found 
on a significant number of genes (113-115). TCDD-mediated immunosuppression may 
involve multiple pathways because AhR ligation leads to activation of DREs found on a 
significant number of genes (36-38), including those involved in the regulation of 
immune response.  Some mechanistic pathways that have been previously identified 
include: induction of Fas that expresses DRE on its promoter and upregulation of FasL 
leading to enhanced activation-induced cell death/apoptosis (84, 85, 87, 114, 116, 117), 
upregulation of FoxP3 which also expresses DREs thereby leading to induction of Tregs 
(88, 89) increased induction of Tregs while suppressing Th17 cells via epigenetic 
regulation (50),  and the like.  In addition to Tregs, it is increasingly becoming clear that 
MDSCs also play a critical role as regulators of inflammation (103, 118, 119). Whether 
AhR activation can lead to induction of MDSCs in naïve mice has not been investigated 
thus far, and therefore formed the rationale for the pursuit of the current study.  
Interestingly, we found that TCDD treatment led to robust induction of MDSCs in naïve 
animals in a dose-dependent manner and such an induction was AhR-dependent.  It has 
been reported that there are two groups of interconnected signals in MDSCs 
accumulation and activation. First group of signals is responsible for immature myeloid 
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cells expansion whereas, the second group of signal is responsible for their activation and 
promotion of pathologic activity (27). First group includes GM-CSF, M-CSF, G-CSF, IL-
6, VEGF and polyunsaturated fatty acids and signals primarily via STAT3 and STAT5. 
However this signaling alone is not sufficient without second activating signal which is 
mainly provided by pro-inflammatory molecules such as interferon-γ (IFN-γ), IL-1β, IL-
4, IL-6, IL-13, tumor necrosis factor (TNF), TLR ligand, and signals that utilize NF-κB, 
STAT1, and STAT6 transcription factors for their activation (27-29). In the current study, 
we found that induction of MDSCs in the peritoneal cavity was associated with increases 
in several chemokines such as CCL2, CCL3, CCL4, CCL11, CXCL1, CXCL2, CXCL5 
and CXCL9.  Also, the observation that TCDD caused a decrease in MDSCs in the bone 
marrow while an increase in the peritoneal cavity suggested that TCDD-induced 
chemokines in the peritoneal cavity may have caused MDSC mobilization from bone 
marrow to peritoneal exudate. This was also supported by the observation that TCDD 
treatment led to a significant decrease in BM-MDSCs with a consequent increase in 
peritoneal MDSCs.  Additionally, we found that the peritoneal MDSCs induced by 
TCDD were not actively dividing thereby supporting the migration rather than in situ 
proliferation of MDSCs.  We noted that TCDD treatment also caused activation of 
MDSC and their functions.  Energy metabolic pathway(s) used by MDSCs may play a 
critical role on the immunosuppressive functions of MDSCs and increase in this pathway 
is a sign for high immunosuppressive activity of cells (26).  We observed that TCDD-
induced MDSCs had higher oxygen consumption rates (OCR), proton efflux rate (PER) 
and ATP rate. TCDD-induced MDSCs also exhibited significant increase in cell lineage-
specific transcription factors and cytokines including IL-10, PIM1, STAT3, and ARG2.   
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Chemokines and their receptors such as CCL5, CXCL17, CXCL2, CCR5 and CXCR2 
play a critical role in MDSCs migration from bone marrow to tumor environment (120-
122). Furthermore, we observed increased expression of chemokines receptors post-
TCDD administration on MDSCs such as CCR1 (receptor for CCL3 and CCL4), CCR5 
(receptor for CCL4 and CCL11) and CXCR2 (receptor for CXCL1, CXCL2 and CXCL5) 
(Fig 2.3E).  One of the chemokine receptors that is expressed on MDSCs that has 
effective role in MDSC migration is CXCR2. Thus, CXCR2-deficient mice showed 
significantly decreased MDSC induction, in an inflammatory models of endometriosis 
when compared to wild-type mice (123). Also, we found in the current study that 
blocking CXCR2 using an antagonist Sch527123, reduced TCDD-mediated MDSC 
induction (Fig 2.3F). Importantly, a second signal that is involved in MDSC 
accumulation includes GM-CSF, G-CSF, M-CSF, and VEGF (23, 124), and we found an 
increase in these factors in both serum and peritoneal exudate of TCDD-treated group 
when compared to vehicle (Fig 2.3C-D). These data together suggested that TCDD-
induced upregulation of chemokines and their receptors were responsible for the 
migration and accumulation of MDSCs in the peritoneal cavity.  We were surprised to 
see that TCDD induced many chemokines and thus, we checked to see if such 
chemokines may be induced following AhR activation involving DREs.  To that end, we 
performed in silico analysis to address if the chemokine promoters expressed DREs.   
Such an analysis demonstrated that several chemokines expressed DREs on their 
promoters (Table 2).   
 MDSCs constitute a heterogeneous population of cells representing a pathological 
state of activation of myeloid cells that have acquired a highly immunosuppressive 
31 
 
phenotype (125). These cells are of great interest in cancer as well as in inflammation as 
they potently suppress the cytotoxic activities of natural killer and natural killer T cells, 
and immune responses mediated by CD4 and CD8 T cells (120, 126). Under normal 
conditions, precursor myeloid cells from bone marrow differentiate into mature 
granulocytes, macrophages or dendritic cells as they home to peripheral organs. 
However, enhanced mediator  production during pathological conditions such as cancer, 
infections, trauma, inflammation and autoimmunity, as well as sometimes in response to 
certain natural compounds, there is proliferation of immature myeloid cells while 
blocking their terminal differentiation resulting in the accumulation of 
immunosuppressive MDSCs phenotype (121).  Recent studies from our laboratory have 
demonstrated the induction of MDSCs as an important mechanism through which several 
natural compounds exert immunosuppressive or anti-inflammatory properties, including 
marijuana cannabinoids, and resveratrol (103, 108, 122, 127) 
 Functional analysis of TCDD-induced MDSCs showed potent 
immunosuppressive effects on T cell proliferation in vitro. We noted that while both G-
MDSC and M-MDSCs were immunosuppressive against T cell proliferation in vitro, the 
latter cells were more potent.  In the current study, we also demonstrated that TCDD-
induce MDSCs were functionally immunosuppressive in vivo as well.  Thus, upon 
adoptive transfer of TCDD-induced MDSCs in to ConA-injected mice, there was 
significant protection of liver form acute inflammation. This was found to be associated 
with increased polarization of Th2 cells and Tregs and decreased induction of Th1 and 
Th17 cells, along with increased production of anti-inflammatory cytokines TGF-β and 
IL-4 levels in these mice (Fig 2.5A-E). These data are consistent with our previous 
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studies demonstrating that MDSCs induced by cannabinoids can suppress ConA-induce 
hepatitis in vivo upon adoptive transfer (103). Importantly, we also noted that 
administration of TCDD into ConA-injected mice also led to protection of liver and in 
such mice, we also saw similar cell phenotypes including increased presence of MDSCs, 
Th2 cells, Tregs, and subsets of Tregs but a decrease in the induction of Th1 cells (Fig 
2.6). MDSCs can induce Tregs through disruption Th17/Treg balance because MDSCs 
have the potential to convert Th17 cells into Foxp3
+
 Treg and enhance shifting the 
immune response from inflammation to tolerance (128),  which can also be mediated by 
increase of IL-10 or TGF-β production (101, 129).  
  Several studies have shown that miRNA play an influential role in the toxicity of 
TCDD in animal models (116, 130-133). Studies have also shown that miRNA play a 
critical role in the regulation of MDSCs in different diseases models (65, 104, 134-136).  
For example, inhibition of miRNA-9 has been shown to promote the differentiation of 
MDSCs whereas, overexpression of miRNA-9 markedly enhanced the function of 
MDSCs (137). Also miRNA-155 and miRNA-21 were the two most upregulated 
miRNAs during the induction of MDSCs from the bone marrow cells by GM-CSF, IL-6 
and TGF-B (36). Chen and his colleagues found that miRNA-17-5p, miRNA-20a, 
miRNA-223, miRNA-21, miRNA-155, miRNA-494, miRNA-690, and miRNA-101 are 
of particular interest for tumor MDSCs accumulation and function (138). In this study, 
we also observed that TCDD-induced MDSCs exhibited significant down-regulation in 
the expression of miRNA including miR-150-5p and miR-543-3p. Upon further 
characterization of these two miRNAs, we observed that these two miRNAs targeted 
several anti-inflammatory genes IL-10, PIM1, ARG2, STAT3, and  CCL11 and 
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chemokines receptors  CCR3, CCR5, and CXCR2.  Transfection studies confirmed that 
these miRNAs caused upregulation of these anti-inflammatory genes.  IL-10, ARG2, and 
STAT3 have been well characterized for their ability to downregulate the production of 
pro-inflammatory cytokines such as INF-γ, IL-2, IL-3, and TNF-α (122, 127). 
Additionally, STAT3, a transcription factor, is a hallmark of MDSCs, as STAT3 is 
directly involved in the accumulation and expansion of MDSCs in humans and mice. 
Arg2 found in MDSCs is directly involved in depleting l-arginine availability for T cells 
in the inflamed microenvironment and thus inhibit T-cell proliferation. MDSCs not only  
suppress T cell activation by IL-10 production but also by interacting with macrophages 
to increase IL-10 production and decrease IL-12 secretion (139-141). PIM1 is a member 
in serine/threonine kinases family that has two members, PIM2 and PIM3 in addition to 
PIM1 and have been implicated in the regulation of apoptosis, metabolism, cell cycle, 
and migration. PIMI was observed to be overexpressed in numerous solid tumors and was 
accompanied by MDSCs accumulation (142). From the current study, we noted that 
CCL11 and its receptors CCR3 and CCR5 were specifically embroiled in MDSCs 
migration from bone marrow to peritoneal exudate. Analysis using ingenuity pathway, 
shed light on the relationship of STAT3, IL-10, PIM1, ARG2, CCL11, CCR3, CCR5, and 
CXCR2 and the two downregulated miRNAs, miR-150-5p that targets IL-10 and PIM1 
and miR-543-3p that targets ARG2, STAT3, CCL11, CCR3, CCR5, and CXCR2.   
 In summary, the present study demonstrates for the first time that activation of 
AhR triggers massive accumulation of MDSCs even in naïve mice without any 
inflammatory signal, resulting from induction of chemokines and their receptors.  
Furthermore, we observed that TCDD also causes changes in the expression of miRNA 
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within the MDSCs and alter gene expression that promote their anti-inflammatory 
functions.  AhR activation is a double-edged sword.  On one hand AhR plays a key role 
in intestinal homeostasis.  Thus, deficits in AhR signaling have been linked to 
experimental and human intestinal bowel disease (143). On the other hand, AhR ligands 
such as the environmental contaminants, TCDD or methylcholanthrene (3-MC), are 
highly toxic and are considered to be carcinogens.  Interestingly, this dual-action of AhR 
activation also correlates with that of MDSCs which are known to suppress inflammation 
and autoimmune disease (144) as well as promote tumor development and progression 
(145). Further studies aimed at addressing the nature of AhR-induced MDSCs in the 





Figure 2.1: TCDD induces MDSCs in naïve mice. Naïve C57BL/6 mice were injected 
with TCDD or vehicle i.p. and at various days post-treatment, cells from the peritoneal 
cavity were harvested and analyzed for MDSCs.  (A) Representative plots from flowjo 
software analysis of flow cytometry data showing induced in MDSC percentages 
following 1, 5, or 10 µg/kg TCDD administration when compared to vehicle. Cells were 
harvested on day three (B) Total number of MDSCs/mouse expressed as mean+/-SEM 














percentages following administration of 1, 5, or 10 µg/kg TCDD when compared to 
vehicle. (D) Total number of monocytic and granulocytic MDSCs/mouse expressed as 
mean+/-SEM. (E) Time-course of induction of MDSCs. (F) Total number of 
MDSCs/mouse at different days expressed as mean+/-SEM. (G) Representative plots 
showing M-MDSCs and G-MDSCs after 3 days of 10 µg/kg TCDD treatment when 
compared to vehicle.  (H). Total number of MDSCs/mouse after 3 days following 10 
µg/kg TCDD administration, expressed as mean+/-SEM. Statistical analysis was 
performed using Student’s t test and one-way analysis of variance (ANOVA) *p < 0.05; 




Figure 2.2: AhR   antagonist CH223191 treatment decreases TCDD-mediated 
MDSC induction.  Naïve C57BL/6 mice were injected with TCDD (10 µg/kg) i.p. as 
described in Fig 1 legend.  These mice were injected i.p with 10 mg/kg of AhR antagonist 
(CH223191) one day before TCDD injection. Peritoneal exudates were collected in day 3 
and stained for MDSCs. (A) Representative flow cytometric analysis showing MDSC 
percentages after treatment with AhR antagonist. (B) Total number of MDSCs/mouse 
expressed as mean+/-SEM following treatment with AhR antagonist, based on panel A 
description. (C) Representative flow cytometric analysis showing percentages of MDSC 
subsets after treatment with AhR antagonist. (D) Total number of MDSC subsets /mouse 
expressed as mean+/-SEM following treatment with AhR antagonist. One-way analysis 
of variance (ANOVA) was used to compare between the groups *p < 0.05; **p < 0.01; 




Figure 2.3: Identifying the source of TCDD-induce MDSCs. Naïve C57BL/6 mice 
were injected with TCDD (10 µg/kg) i.p. as described in Fig 1 legend.  (A) 
Representative flow cytometric analysis showing that percentage of MDSCs in bone 
marrow 16 hrs after TCDD treatment when compared to 0 hr. Contrary, MDSCs 
percentage increased in peritoneal cavity after 16 hrs compared to 0 hr. (B) Total number 
of MDSCs/mouse expressed as mean+/-SEM based on panel A description (C) 
Measurement of chemokines in peritoneal exudate with data expressed as mean+/-SEM. 
(D) Detection of chemokines in the serum with data expressed as mean+/-SEM. (E) Q-
PCR validation of CCR1, CCR5 and CXCR2 expression in TCDD compared to vehicle, 
with data expressed as mean+/-SEM. (F) Flow cytometric analysis of MDSC percentage 
and absolute numbers following treatment with TCDD and CXR2 antagonist. Vertical 
bars represent total cellularity/mouse expressed as mean+/-SEM.  (G) Representative 
plots of  BrdU labeling and anti-Ki67 staining at 48 h post-TCDD treatment.  The left 
panel shows staining for MDSCs and right panel shows staining for BrdU and Ki67 on 
gated MDSCs. Vertical bars represent mean ± SEM. Student’s t test and One-way 





Figure 2.4: TCDD-induced MDSCs suppress T cell proliferation and exhibit 
different metabolic profile. (A-C) TCDD-induced purified peritoneal MDSCs as well as 
monocytic and granulocytic MDSCs were incubated with spleen cells activated with 
ConA at different ratios and T cell proliferation was assessed by 3H-thymidine 
incorporation assay. Data are depicted as mean ± SEM of triplicate cultures shown as 
counts per minute (CPM). (D,E) Oxygen consumption rate (OCR) and Glycolytic proton 
efflux rate (GRE) TCDD-induced MDSCs compared to vehicle-induced MDSCs. (F). 
ATP production rate in the experimental groups. Student’s t test was used to compare 




Figure 2.5: TCDD-induced MDSCs protect from ConA-induced liver damage and  
inflammation in vivo following adoptive transfer. C57BL/6 mice were injected 
intravenously with Con-A (12.5mg/kg) and these mice received 1 hr before, adoptive 
transfer of 5 million purified MDSCs from peritoneal cavity (PC-MDSCs) or bone 
marrow MDSCs (BM-MDSCs) from TCDD-treated mice.  Mice were sacrificed after 48 
hrs post treatment for further analysis.  (A) H&E stain of liver tissue.  (B) Measurement 
of ALT in sera. (C) Measurement of TGF- -4 level in sera.  Percentages of cells 
expressing various cytokines determined by flowcytometry in spleen(E), and liver (F). 




Figure 2.6: TCDD treatment attenuates ConA-induced hepatitis and associated 
inflammation.  ConA was used to induce hepatitis as described in Fig 5 legend.  These 
mice received TCDD (10 µg/kg) by i.p. route, 1 hr before ConA injection followed by 
analysis of spleens and liver for inflammation. (A) ALT level in serum of  hepatitis-
induced mice treated with vehicle or TCDD. (B, C) Percentage and total numbers of 
MDSCs and G-MDSCs in the spleens of two groups respectively.  (D, E) Percentage of 
CD3+CD4+ cells in the spleens, respectively.  (F,G)  Percentages of Th1 and Th4 cells in 
splenocytes showing data from a representative and multiple experiments, respectively.  
(H-L) Elucidation of T-regs and their subsets in spleen cells showing both a 
representative experiment and data from multiple experiments in the form of vertical 





Figure 2.7: TCDD-mediated alterations in miRNA expression in MDSCs. Naïve mice 
were treated with TCDD as described in Fig 1 legend.  The peritoneal MDSCs were 
analyzed for miRNA expression.  (A) Heat map of miRNAs expression in MDSCs from 
vehicle and TCDD groups showing more than 3000 miRNAs. (B) Venn diagram showing 
miRNA that are up or down regulated in TCDD group when compared to vehicle 
controls.  (C) Heat map of up and down regulated (greater than two-fold) of miRNAs in 
vehicle vs TCDD groups. (D) IPA ingenuity software analysis was used to determine 




Figure 2.8: SVR and context alignment between miRNAs and targeted genes. (A,B) 
SVR score and alignment (miRNA.org) between mir-150-5p and targeted genes (IL-10 
and PIM1) as well as between  mir-543-3p and targeted genes (ARG2 and STAT3). (C) 
Context score and alignment (targetscan.org) between mir-543-3p and CCL11, CCR3, 





Figure 2.9: Q-PCR analysis of miRNA-150-5p and miRNA-543-3p and specific 
targeted genes.  MDSCs were isolated as described in Fig 1 legend.  (A)  Expression of 
mir-150-5p and mir-543-3p in TCDD-induced MDSCs when compared to vehicle. (B). 
Expression of targeted genes IL-10, PIM1, ARG2, STAT3, CCL11, CCR3 and CCR5 in 
TCDD-induced MDSCs when compared to vehicle. MDSCs was transfected with mimic 
and inhibitor of both mir-150-5p and mir-543-3p (C) mir-150-5p expression with mimic 
compared to mock and inhibitor. (D) Expression of IL-10, PIM1 with inhibitor of mir-
150-5p compared to mock and mimic of mir-150-5p. (E) Expression of mir-543-3p with 
mimic compared to mock and inhibitor. (F) Expression of ARG2, STAT3, CCL11, 
CCR3, and CCR5 in the presence of inhibitor of mir-543-3p compared to mock and to 




Table 2.1:  The forward and reverse primers for listed genes: 
Gene Primer Sequences (5’-3') 
PIM1 Forward TTCTGGACTGGTTCGAGAGG 
 Reverse TGTTCTCGTCCTTGATGTCG 
Arg2 Forward TGTCATCTGGGTTGATGCTC 
 Reverse CAGGAGGCTCCACATCTCTC 
IL-10 Forward CCCATTCCTCGTCACGATCTC  
 Reverse TCAGACTGGTTTGGGATAGGTTT 
STAT3 Forward CAATACCATTGACCTGCCGAT  
 Reverse GAGCGACTCAAACTGCCCT  
CCL11 Forward GAATCACCAACAACAGATGCAC 
 Reverse ATCCTGGACCCACTTCTTCTT 
CCR1 Forward CTCATGCAGCATAGGAGGCTT 
 Reverse ACATGGCATCACCAAAAATCCA 
CCR3 Forward TCAACTTGGCAATTTCTGACCT 
 Reverse CAGCATGGACGATAGCCAGG 
CCR5 Forward TTTTCAAGGGTCAGTTCCGAC 
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 Reverse GGAAGACCATCATGTTACCCAC 
CXCR2 Forward ATGCCCTCTATTCTGCCAGAT 
 Reverse GTGCTCCGGTTGTATAAGATGAC 
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Table 2.2: Number of the sequences sites of the dioxin responsive element (DRE) on the 





Number of DRE Sequence 
Sites   






CCL2 1 2 AL626807.7  
CCL3 1 2 AL596122.14  
CCL4 1 2 AL596122.14  
CCL11 2 2 AL645596.7  
CXCL1 1 4 AC157938.9 
CXCL2 2 5 AC157938.9 
CXCL5 2 2 AC105995.9 
CXCL9 3 4 AC109603.8  
CXCR2 3 0 AC117757.23 
miR-150-5p 19 11 AC126256.4 




AHR ACTIVATION LEADS TO ALTERATIONS IN THE GUT MICROBIOME 
WITH CONSEQUENT EFFECT ON INDUCTION OF MYELOID DERIVED 
SUPPRESSER CELLS IN A CXCR2-DEPENDENT MANNER 
 
3.1 ABSTRACT 
 Aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor and 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a well-documented environmental 
halogenated aromatic hydrocarbon, is a potent ligand for AhR.  Thus, AhR activation by 
TCDD leads to significant immunomodulation.  Recent studies have shown that immune 
system homeostasis is also maintained by gut microbiota.  Thus, whether TCDD-
mediated regulation of immune response occurs through cross talk with gut microbiota is 
unclear.  Previously, we observed that activation of AhR by TCDD in C57BL6 mice 
leads to massive mobilization of myeloid derived suppresser cells (MDSCs).  In the 
current study, we observed that TCDD caused significant alterations in gut microbiome, 
specifically, increasing the abundance of several Prevotella and Lactobacillus at the 
genus level while decreasing Sutterella and Bacteroides.  Fecal material transplantation 
(FMT) from TCDD-treated donor mice into antibiotic treated (ABX) mice induced 
MDSCs and MDSC subsets as well as increased Tregs. Injecting TCDD directly into 
ABX mice also induced MDSCs but to a much lesser degree than in naïve mice.  These 
data suggested that TCDD-induced dysbiosis plays a critical role in MDSC induction.  
Interestingly, treatment with TCDD led to induction of MDSCs in the colon and 
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undetectable levels of cysteine.  MDSCs suppressed T cell proliferation while 
reconstitution with cysteine restored this response.  Lastly, blocking CXCR2 impeded 
TCDD-mediated MDSC induction. Our data demonstrate that AhR activation by TCDD 
triggers dysbiosis which in turn regulates, at least in part, induction of MDSCs.    
3.2 INTRODUCTION 
 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an environmental pollutant 
generated during the manufacture of herbicides or burning organic materials such as 
waste incarnation, fossil fuel, and wood combustion (146). Ingestion of contaminated 
food is one of the most common  exposures of TCDD in humans (40). Following TCDD 
exposure, immune cells such as regulatory T cells (Tregs) are expanded and effector T-
cells are suppressed (147), in addition to depletion of macrophages and dendritic cells in 
jejunum (148, 149). A single dose of oral TCDD administration decreased 
immunoglobulin (Ig) A secretion in the gut by impairing B-cell function (150).  The gut 
is lined with a single layer of epithelia cells connected by tight junction proteins and is 
interspersed with mucus-secreting goblet cells and paneth cells which release 
antimicrobial peptides (151). Interestingly, mice treated orally with TCDD developed 
tolerance to ovalbumin (OVA) and showed suppression in the humoral immune response 
in the epithelial cells of lumen, as well as serum and fecal samples (152). However, in 













 by TCDD occurred only in the gut-specific draining lymph node 
(MLN).   
 The diversity of microbes within a given host can be defined by the number, 
abundance, and distribution of distinct types of organisms such as bacteria, archaea, 
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protists, fungi and viruses. The interaction and activity of these microbes has been linked 
to the homeostasis of immunologic, hormonal, and metabolic processes of the host. 
Microbial dysbiosis and alterations in the microbiome with negative effects on the host, 
occurs due to a wide range of causes such as diseases, environmental contamination, diet, 
and stress (52-54). The gastrointestinal tract is the largest habitat of the microbiota, and 
emerging studies have shown that TCDD exposure leads to its rapid absorption into the 
gastrointestinal tract which can cause shifts in gut microbiome commensals (55, 153). 
Nonetheless, whether there is a link between immunological changes induced by TCDD 
and the gut microbiota has not been previously studied.    
 Most of the activity of TCDD is mediated through the aryl hydrocarbon (AhR), a 
cytosolic-bound receptor expressed in a variety of immune cells including T-cells, 
monocytes, granulocytes, myeloid-derived suppressor cells (MDSCs), and mast cells. 
AhR activation by TCDD leads to alterations in the immune system involving several 
mechanisms such as  disruption  of the Treg/Th17 balance, suppression of the cytotoxic 
T-cells response,  impairment of antibody production by B cells in a T cell dependent 
manner, and decrease in IL-6 and TNF production by macrophages, and induction of 
apoptosis in activated T cells (50, 87, 114, 154-156).  TCDD is also well-characterized 
for its ability to induce Tregs (50, 157). Recently, we observed that TCDD administration 
leads to massive induction of MDSCs that are highly immunosuppressive (manuscript 
under review). Thus, in the current study, we investigated if the microbiota of the host 
plays any role in the induction of MDSCs by TCDD. 
 Using 16S rRNA sequencing of the gut microbiome, we noted that TCDD 
exposure resulted in alterations of the gut microbiome, and metabolome, such as 
50 
 
reduction in cysteine metabolism. Importantly, using fecal material transfer (FMT) 
experiments we found that MDSC induction by TCDD was dependent, at least in part, by 
the gut microbiota. 
3.3 MATERIAL AND METHODS 
Animals 
 Female C57BL/6 adult mice were purchased from Jackson laboratory (Bar 
Harbor, MA). All the animals were housed in the Animal Research Facility (ARF) 
located at the University of South Carolina (USC) under pathogen-free conditions. Mice 
were cared for in accordance with the NIH guideline for use of laboratory animals under 
protocols approved by the university Institutional Animal Care and Use Committee 
(IACUC) at USC.   
Chemicals and reagents 
 TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences & 
Technology, Texas A&M Health Sciences Center, College Station, Texas). Culture 
medium reagents (RPMI 1640, Bacitracin, Gentamycin, Ciprofloxacin, Neomycin, 
Penicillin, Metronidazole, Ceftazidime, Streptomycin, and Vancomycin from Sigma-
Aldrich (St. Louis, MO). HEPES, L-Glutamine, FBS, and PBS) were purchased from 
Invitrogen Life Technologies (Carlsbad, CA). The following antibodies were  purchased 
from Biolegend (San Diego, CA) and used for surface markers, intra-cellular and/or intra-
nuclear staining: Alexa Fluor 700-conjugated anti-CD11b,  BV510-conjugated-GR-1, 
Alexa Fluor 488-conjugated anti-Ly6C, BV785-conjugated anti-Ly6G,  BV785-
conjugated anti-CD4, PE-conjugated anti-CD3,  Alexa Fluor 488-conjugated anti-IL-17, 
BV605-conjugated anti-IL-10, BV650-conjugated anti-INF-ƴ, BV421-conjugated anti-
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IL-4, BV510- conjugated anti-FOXP3 and, APC-conjugated anti-CD25. FC Block and 
monoclonal Mouse IgG anti-Arg1 were purchased from BD Biosciences (San Diego, 
USA). Monoclonal Rat IgG antibodies of CD11b and Ly6G/Ly6C (Gr-1) were purchased 
from Biolegend (San Diego, CA). Cytofix/CytopermTM Fixation/ Permeabilization kit 
was purchased from BD Biosciences. True-Nuclear™ Transcription Factor Buffer Set 
was purchased from BioLegend. EasySep™ PE Positive Selection Kits were purchased 
from Stem Cell Technologies (Vancouver, BC, Canada). N acetyl-cysteine (NAC) and 
CXCR2 antagonist Sch527123 were purchased from Sigma-Aldrich (St. Louis, MO). 
Cysteine Assay Kit was purchased from Abcam (Cambridge, United Kingdom).  
TCDD Exposure and 16S rRNA amplicon sequencing 
 Female C57BL/6 between 6-8 weeks were injected i.p. with TCDD (10 µg/kg) or 
Vehicle (corn oil), as described previously (116, 158). Feces from individual mouse were 
collected from TCDD- or Vehicle-treated mice or from naïve mice, three days post 
treatments and kept in -80
0
C for later use. 16S rRNA sequencing and analysis were 
performed as previously described (159). QIAamp DNA Stool Mini Kit (Qiagen) was 
used for DNA isolation from fecal pellets (100 mg) of the three groups following the 
protocol of the company (Qiagen). Genomic DNA samples were quantified by using 
nanodrop system (Thermo Scientific) and kept in -80
0
C for further use. Amplification of 
the 16S rRNA V3–V4 hypervariable region was carried out using the 16S V3 314F 
forward (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGC 




GACAGGACTACHVGGGTATCTAATCC-3′). The Illumina overhang adapter 
sequences to be added to locus‐specific sequences are: 
Forward overhang: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
Reverse overhang: 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
The PCR program used were 3 min at 95°C, followed by 25 cycles of 30 s at 95°C, 30 s 
at 55°C, and 30 s at 72°C and a final extension at 72°C for 5 min. Each reaction mixture 
(25 μl) contained 50 ng of genomic DNA, 0.5 μl of amplicon PCR forward primer (0.2 
μM), 0.5 μl of amplicon PCR reverse primer (0.2 μM), and 12.5 μl of 2× KAPA Hifi Hot 
Start Ready Mix. AMPure XP beads were used for each reaction to purify the 16S V3 
and V4 amplicon away from free primers and primer dimer species. Attachment of dual 
indices and Illumina sequencing adapters was performed using the Nextera XTIndex Kit 
includes 5 μl of amplicon PCR product DNA, 5 μl of Illumina Nextera XT Index Primer 
1 (N7xx), 5 μl of Nextera XT Index Primer 2 (S5xx), 25 μl of 2 × KAPA HiFi Hot Start 
Ready Mix, and 10 μl of PCR-grade water. Amplification was carried out under the 
following program: 3 min at 95°C, followed by 8 cycles of 30 s at 95°C, 30 s at 55°C, 
and 30 s at 72°C, and a final extension at 72°C for 5 min. Constructed 16S metagenomic 
libraries were purified with AM Pure XP beads and quantified with Quant-iTPicoGreen. 
Libraries were quantified using a fluorometric quantification method that uses dsDNA 
binding dyes. DNA concentration was calculated in nM based on the size of DNA 
amplicons as determined by an Agilent Technologies 2100 Bioanalyzer trace.  Libraries 
were normalized and pooled to 40 nM based on quantified values. Pooled samples were 
denatured and diluted to a final concentration of 8 pM with a 30% PhiX (Illumina) 
control. Samples then were loaded, and results were provided by MiSeq Reporter 
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software (MSR). The Metagenomics workflow classifies organisms from V3 and V4 
amplicon using a database of 16S rRNA data. The classification is based on the 
Greengenes database (http://greengenes.lbl.gov/). The output of this workflow is a 
classification of reads at several taxonomic levels: kingdom, phylum, class, order, family, 
genus, and species. The online 16S analysis software from the National Institutes of 
Health (Nephele) was used to analyze sequencing data collected on the Illumina MiSeq. 
The groups of related DNA sequences were assigned to operational taxonomic units 
(OTUs), and output files were analyzed to determine gut microbial composition. The 
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt) option during Nephele analysis was used to examine differences Level 2 (L2) 
and Level 3 (L3) KEGG pathways using collected 16S rRNA sequencing data. In order to 
differentiate significant alterations within the gut microbiome from experimental 
samples, linear discrimination analysis of effect size (LeFSe) was used as previously 
described (160). 
Short chain fatty acid (SCFA) analysis 
 SCFAs were quantified as previously described by Mehrpouya-Bahrami et al 
(161). In brief, 100 mg cecal contents were acidified by metaphosphoric acid and allowed 
to sit on ice for 30 min. After centrifugation of acidified samples at 12,000xg for 15 min 
at 4
0
C, supernatants were collected and filtered using MC filters at 12,000xg for 4 min in 
4
0
C. MTBE (400 µL) from Sigma (650560) was added to each sample after transferring 
samples in to glass vials. The samples were then centrifuged down at 1300 rpm for 5 min 
at RT and the top organic layer was transferred to a new vial. The standard mixtures with 
the internal standard were used to determine the response factors and linearity for each 
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SCFA standard acid.  A HP 5890 gas chromatograph configured with the flame-
ionization detector (GC-FID) for analysis of volatile organic compounds was used to 
detect the concentration of propionic, n-butyric, isovaleric, valeric, isobutyric, caproic, 
and n-heptanoic acid in the samples.  
Depletion of the gut microbiota 
 Depletion of the gut microbiome was achieved using a  cocktail of antibiotics 
(ABX) consisting of  the following: Bacitracin 1 mg/ml, Gentamycin 170 µg/ml, 
Ciprofloxacin 125 µg/ml, Neomycin 100 µg/ml, Penicillin 100 U/ml, Metronidazole 100 
µg/ml, Ceftazidime 100 µg/ml, Streptomycin 50 µg/ml, and Vancomycin 50 µg/ml, as 
previously described  (96, 162, 163) ABX treatment lasted for 24 days and was supplied 
in the drinking water. Feces for transfer experiments were collected from individual 
mouse under sterile conditions. To validate microbiome reduction, DNA was isolated 
using QIAamp DNA Stool Mini Kit (Qiagen) and analyzed by performing agarose gel 
electrophoresis. DNA Fragments were visualized by Imaging Chemi-Blots on the Bio-
Rad ChemiDoc XRS HQ. Band density of DNA from ABX-treated mice were compared 
to band density of DNA from WT control mice.  In addition, swabs from ABX-treated 
mouse and control feces were cultured in aerobic and anaerobic conditions 2 days. ABX 
treatment was stopped on day 25, and mice to be inoculated with fecal material were co-
housed with Vehicle and TCDD donors on day 26, followed by all subsequent treatments 
given to mice on day 27.         
Fecal material transplantation (FMT)  
 FMTs were performed to determine the effects of TCDD on the gut microbiome 
after TCDD treatment. Donor mice were divided into two groups (n=8 per group). One 
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group was injected with 10 µg/kg i.p. injections of TCDD (T), and the second group was 
treated with corn oil as the vehicle (V). After 3 days, colon contents were collected under 
sterile and anaerobic conditions for dilution in sterile PBS. ABX-treated mice were 
divided into 5 groups (n=4-5 per group) and treated as follows:  untreated, treated 
butyrate in their drinking water (1% sodium butyrate), with TCDD (10 µg/kg) (TCDD); 
with FMTs from vehicle treated mice (VFMT); FMT from TCDD-treated mice (TFMT).   
The mice were euthanized after three days using isoflurane overdose to collect cells from 
peritoneal exudates, spleens, and blood.     
Flow cytometry to evaluate immune cell phenotypes   
 MDSCs and MDSCs subsets were stained and identified as described by us 
previously (103).  Cells were harvested from peritoneal cavity of recipient and treated 
mice and stained with fluorescently-labeled antibodies (Biolegend and BD Biosciences) 
for phenotyping. Antibodies included Alexa Fluor 700-conjugated anti-CD11b, BV510-
conjugated-Gr-1, Alexa Fluor 488-conjugated anti-Ly6C and BV785-conjugated anti-
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).  For T helper and transcription factor FOXP3 staining, 
antibodies used were BV785-conjugated anti-CD4, PE-conjugated anti-CD3, Alexa Fluor 
488-conjugated anti-IL-17, BV605-conjugated anti-IL-10, BV650-conjugated anti-IFN-γ, 
BV421-conjugated anti-IL-4, and BV510-conjugated anti-FOXP3 to detect  the following 























). Flow cytometry analysis was performed 
using BD FACs Celeste and FlowJo software from ThermoFisher Scientific.  
56 
 
Real-Time (RT-PCR)  
 DNA was isolated from feces of experimental groups using QIAamp DNA Stool 
kit from Qiagen (Valencia, CA), and samples were diluted to 1ng/µl concentrations. 
MiScript primer assays kit and miScript SYBR Green PCR kit from Qiagen were used to 
perform PCRs following the protocols provided by the company. Sutterella and 
Lactobacillus PCR primers were purchased from IDT Technologies with primer 
sequences based on previous publications (164, 165).  Cystathionase, XCT, 4F2 and ASC 
primers were designed based on a  previous publication (120). The PCR products, 
generated from mouse gene-specific primer pairs or bacteria-specific primers pairs, were 
visualized with UV light performing electrophoresis (1.2% agarose gel). The band 
intensity of PCR products was determined using ChemiDoc image analysis system from 
Bio-Rad (Bio-Rad, Hercules, CA). The expression of the above genes were normalized 
against PCR products generated from mouse housekeeping gene GAPDH or against PCR 
product generated from Eubacteria gene (internal controls) as previously reported (67).  
Purification of MDSCs  
 TCDD-induced MDSCs from the exudates of peritoneal cavities were purified as 
previously described using selection of Gr-1
+
 MDSCs (119). In brief, peritoneal exudates 
were collected from TCDD-exposed mice and after washing the cells two times with 
PBS, cells were labeled with a PE-conjugated Gr-1 antibody from Biolegend and 
magnetically sorted using a Positive Mouse PE Selection kit from Stem Cell 





[3H] thymidine incorporation assay   
 To measure the proliferation of T-cells, splenocytes (5x10
5
) from C57BL/6 naïve 
mice were cultured in the presence of Con A (2 µg/ml) in medium deficient in N-acetyl-
cysteine (NAC) or with NAC (0.5 Mm) in a 96-well round bottom plate. The cells were 
cultured alone or cultured together with TCDD-induced peritoneal MDSCs in the ratio of 
1:0.5 overnight. [3H] thymidine (1 µCi/well) was added to the cell cultures, and after 18 
hrs radioactivity was measured using a MicroBeta Trilux liquid-scintillation counter 
(PerkinElmer Life and Analytical Sciences).      
Detection of Cysteine level in peritoneal exudate, and colon exudate  
 Cysteine concentration was assessed in peritoneal and colon exudates collected 
from mice that received TCDD treatment using a fluorometric Cysteine Assay Kit 
(ab211099) from Abcam following the protocol from the manufacturer. Delta 
corresponding fluorescence values (∆ RFU) were calculated and applied to the cysteine 
standard curve to calculate reaction concentration.  
Fluorescence staining of colon tissue sections 
 Colon tissue samples from three groups (Vehicle, TCDD, and 
TCDD+Sch527123) were fixed in 4% paraformaldehyde diluted in PBS overnight. Fixed 
colons were sectioned (5 µm thick) and placed on coated slides. Slides were incubated for 
30 min in glycine 0.1% and 1x triton for tissue permeabilization for Arg1 staining or with 
glycine 0.1% only for CD11b and Gr-1 staining. Slides were then incubated with primary 
mouse anti-Arg1 antibodies or primary rat anti-CD11b and anti-Gr-1 antibodies 
purchased from Cell Signaling (Danvers, MA) at 4
0 
C overnight, followed by a 2 hour 
incubation at room temperature with secondary Alexa Fluor 488 goat anti-mouse IgG 
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antibody for Arg1, Alexa Fluor 488 goat anti-rat IgG for CD11b, and Cy5 goat anti-rat 
IgG antibody for Gr-1. Fluorescent imaging of colon sections was taken using a Leica 
DM 2500 optical microscope from Leica Microsystems (Buffalo Grove, IL). 
Quantification of cell markers was calculated as corrected total cell fluorescence (CTCF) 
using Image J software (National Institutes of Health and the Laboratory for Optical and 
Computational Instrumentation).  
Statistical analysis 
 GraphPad Prism software version 6.01 (San Diego, CA) was used for statistical 
analysis. Student's t-test was used for paired observations if data followed a normal 
distribution to compare between two groups while one-way analysis of variance 
(ANOVA) was used to compare between more than two groups. A P-value of ≤0.05 was 
considered statistically significant. For all experimental results, data was collected from 
at least two independent experiments with consistent results unless otherwise stated. 
3.4 RESULTS 
TCDD exposure alters the gut microbiome composition and SCFA production 
 TCDD is a well characterized high affinity ligand for AhR and therefore, we used 
TCDD to investigate how AhR activation alters the gut microbiota.  16S rRNA 
sequencing with the Illumina MiSeq platform was performed on feces from the following 
groups: wild-type mice (Naïve), mice treated with corn oil (Vehicle), and mice given 
10µg/kg i.p. injections of TCDD (TCDD). Data collected from sequencing showed that 
Vehicle or TCDD treated mice had decreased alpha diversity when compared to naïve 
controls, which was assessed by Chao1 rarefaction measurement (Fig. 3.1A). Beta 
diversity from principle coordinate analysis (PCoA) also showed that Vehicle and TCDD 
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treated mice had gut microbial compositions dissimilar to Naïve mice, however, all 
groups clustered in their own respective treatment niches, suggesting TCDD-treated mice 
had a distinct composition when compared to Vehicle (Fig. 3.1B). However, sequencing 
data and OTU classification from the phylum to genus level showed that TCDD 
treatment had a marked effect on gut microbiome composition (Fig. 3.2-6).   
 In order to differentiate the significantly altered bacteria between all the 
experimental groups, LEfSe analysis was performed on the OTUs from phylum to genus. 
Results showed that there were several bacteria found to be distinctly expressed in the 
Naïve, Vehicle, and TCDD groups.  These included the genus Bacteroides, Sutterella, 
Prevotella, and Lactobacillus (Fig. 3.1C-D). Among this LEfSe-identified bacteria, 
significantly altered OTUs between Vehicle and TCDD-treated mice included Prevotella, 
Sutterella, Lactobacillus, and Bacteroides (Fig. 3.1D). Specifically, after TCDD 
exposure, there was a significant increase in abundance of several Prevotella and 
Lactobacillus at the genus level however, Sutterella and Bacteroides were significantly 
decreased. To confirm the sequencing results, we quantified bacteria abundance from 
feces of experimental groups using bacteria-specific primers by PCR. These results 
confirmed that there was a significant increase (> 4 fold change) of Lactobacillus in 
TCDD-treated groups when compared to Naive and Vehicle groups (Fig. 3.1F). In 
addition, PCR validation experiments confirmed that there was a significant reduction in 
Sutterella (~50%) in TCDD-exposed mice (Fig. 3.1G). The phylogenetic sequencing and 
PCR validation data clearly demonstrated that TCDD exposure caused alterations in the 
microbiome, such as changing the abundance of Lactobacillus and Sutterella populations 
in the gut. 
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 In addition to the phylogenetic data, bacterial metabolomic SCFA production was 
evaluated in the fecal samples from experimental mice exposed to TCDD. Of all the 
SCFAs studied, only two were found to be significantly altered after exposure to TCDD, 
which included acetic acid and butyric acid. Mice injected with TCDD showed 
significant increases in both acetic acid and butyric acid (Fig. 3.1H) when compared to 
Naïve control or Vehicle-treated mice. Taken altogether, these results showed that TCDD 
exposure leads to not only changes in the microbial phylogeny in the gut, but also alters 
some SCFA production as well. 
TCDD-induced fecal microbiota when transferred into ABX mice can trigger 
MDSCs and Tregs.  
 TCDD exposure has been shown to regulate the immune response, particularly in 
suppressing the inflammatory T cell-mediated response (50, 166). Recently, we found 





peritoneal cavity of mice (manuscript under consideration), as also shown (Fig 3.7A 
upper panels and 3.7B), which included both granulocytic-MDSCs and monocytic-
MDSCs (Fig 3.7C upper panels and 3.7D). To further understand the role of microbiota 
in TCDD-mediated MDSC induction, FMT experiments were performed in ABX-treated 
mice. After confirming ABX treatment led to depletion of the gut microbiome (Fig. 3.8), 
various treatments and FMT experiments were performed to evaluate the contribution of 
the microbial changes to MDSC induction. This included fecal microbiota transfer (FMT) 
from Vehicle-treated mice into ABX mice (VFMT+ABX) or from TCDD-treated mice 
into ABX mice (TFMT+ABX).  Interestingly, we observed that TFMT+ABX mice 
displayed higher proportion as well as increased numbers of MDSCs when compared to 
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VFMT+ABX mice (Fig. 3.7A lower panels, and 3.7B).  Also, these MDSC induced in 
TFMT+ABX mice included both G-MDSCs and M-MDSCs (Fig 3.7C lower panels, and 
3.7E).  The FTM experiments were repeated with consistent results (Fig 3.9).  These 
results strongly suggested that the gut microbiome plays a role in TCDD-mediated 
induction of MDSCs. Moreover, when we injected  TCDD directly into ABX mice, we 
were able to induce MDSCs (Fig 3.9), although it was not as robust as injecting TCDD 
into naïve mice (Fig 3.7A upper panels) thereby showing that normal microbiota seen in 
naïve mice does play a role in MDSC induction by TCDD.  We also injected butyrate 
into ABX mice to see if that would induce MDSCs and failed to detect any increase (Fig 
3.9). The data that FMT from TCDD-treated mice into ABX mice could induce MDSCs 
and that TCDD could induce only a weak MDSC response in ABX mice, together 
demonstrated that induction of MDSCs by TCDD was dependent, at least in part, on gut 
microbiota.    
 AhR activation by TCDD, as well as MDSCs have been shown to induce Tregs 
(167, 168). To investigate if transplanted feces from TCDD-treated mice was able to 
induce Tregs, we harvested spleen cells from ABX-treated mice given TFMT or VFMT. 










 Tregs (Fig 3.10C-D). These data showed that induction of Tregs in naïve 
mice by TCDD may also depend, at least in part, on microbiota. 
TCDD reduces cysteine level in colon and peritoneal exudates  
 In addition to phylogenetic data obtained from Nephele of the 16s rRNA 
sequencing data, theoretical analysis of the gut microbiome metabolomic profile was 
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determined using PICRUSt (Fig. 3.11A). Results from this in silico analysis assigning 
OTUs to KEGG pathways showed that TCDD caused a significant reduction in cysteine 
and methionine metabolism (Fig. 3.11B). To validate these findings, expression of 
cysteine-related genes were evaluated using PCR.  Results showed that compared to 
Vehicle-induced peritoneal MDSCs, TCDD-induced peritoneal MDSCs express less 
cystathionase (CTH), the enzyme responsible for converting intracellular methionine to 
cysteine (Fig. 3.11C), as well as plasma membrane ASC (alanine-serine-cysteine 
transporter) neutral amino acid transporter and Xc
- 
and its light (XCT) and heavy chain 
(4F2) components, which are responsible for exporting cysteine and importing cystine 
from environment (Fig. 3.11C). Upon analysis of cysteine levels in the peritoneal and 
colon exudates of treated mice, it was found that cysteine levels were undetectable in 
mice exposed to TCDD, while Vehicle groups showed significant levels (Fig. 3.11D). In 
order to determine the role cysteine plays in MDSC function, proliferation assays were 
performed using ratios of MDSCs and T cells in the presence or absence of cysteine. As 
shown in Fig. 3.11E, upon activation with ConA adding cysteine in the media reduced 
the suppressive effect of MDSCs on the T-cells (Fig. 3.11E). These data demonstrated 
that TCDD exposure significantly impacted cysteine metabolism and this in turn has 
effects on the ability of MDSCs to suppress the activated T cell response. 
TCDD-mediated effects on MDSCs and the gut microbiome are dependent on 
CXCR2  
 CXCR2 is a chemokine receptor important in the recruitment of MDSCs (169).  
Therefore, we investigated the effect of blocking CXCR2 on TCDD-mediated MDSC 
induction in the colon and peritoneal cavity. To test this notion, 50 mg/kg of CXCR2 
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antagonist, Sch527123, was injected in mice one day before treatment with TCDD. Colon 
sections from experimental mice were taken 3 days after TCDD exposure and stained 
with MDSC-specific markers (CD11b, Gr-1 and Arg1). Results showed that CD11b, Gr-
1, and Arg1 expression increased in the colon after injection with TCDD when compared 
to colons from Vehicle-treated mice but this increase was lost in mice treated with the 
CXCR2 antagonist (Fig. 3.12A-D). Results also showed that blocking CXCR2 prevented 
the accumulation of MDSCs in the peritoneal cavity after injecting with TCDD (Fig. 
3.12E-F). Taken together with the FMT results, these data suggested that TCDD-
mediated effect on MSDCs is dependent on CXCR2. 
 3.5 DISCUSSION   
 In the last past several  decades, numerous studies have shown that exposure of 
laboratory animals to TCDD leads to profound immunosuppression (109-112). More 
recent studies have shown that AhR activation by TCDD can suppress the immune 
system in mice by way of induction of Tregs  (9, 49). Previous studies from our lab have 
also shown that TCDD was able to attenuate the clinical and inflammatory markers of 
colitis (50). The gut microbiome consists of trillions of bacteria which are sensitive to 
many endogenous and exogenous factors including diet, age, health condition, life style, 
and environmental exposures (170). A fundamental role of microbiome in the induction, 
education, and function of the host immune system is therefore understandable. In a 
mutually reciprocal relationship, microbial colonization in the host gut affects the 
development of the immune system, but also subtle changes in the immune system has 
effects on the gut microbiome composition (171).  There are few studies on how AhR 
activation or exposure to TCDD can directly or indirectly cause changes in gut 
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microbiota, bile acids, and short chain fatty acid (SCFA) metabolism (172, 173). Previous 
studies have shown that TCDD, when given orally to mice, caused a shift in mouse gut 
commensals (56, 174). TCDD was even shown to play a role in influencing a shift 
favoring bacteria that expressed antimicrobial resistance genes (ARGs) (153).  
 In the current study, we observed significant alterations in the gut microbiome 3 
days after exposure to TCDD. These alterations were characterized by reductions in 
certain bacteria, such as Sutterella, while significant increases in the abundance of other 
bacteria were observed, such as Lactobacillus.  Some studies have reported that a 
decrease in Sutteralla and an increase in Lactobacillus are related to immune tolerance. 
Tang et al. observed that a reduction in Alcaligenaceae and Sutterella levels in normal 
mice after feeding with purple sweet potato polysaccharides caused an increase in anti-
inflammatory cytokines IL-2 and IL-6 (175). Similarly, Pena et al. found significant 
reductions in pro-inflammatory IFN-γ and TNF-α in the spleen of probiotic-treated mice 
using a mixture of Lactobacillus paracasei and Lactobacillus reuteri, which resulted in 
lessening the severity of colitis in IL-10-deficient mice infected with Helicobacter 
hepaticus (176).   
 Alterations in gut microbiome, also leads to changes in bacterial metabolome, 
such as the production of SCFAs. SCFA, like acetic acid, butyric acid, and propionic 
acid, are metabolic end products of undigested complex carbohydrates for bacterial 
fermentation in the colon (177). We observed that the level of two SCFAs, butyric acid 
and acetic acid, were significantly higher in mice exposed to TCDD. Butyrate is known 
to exhibit tolerance-inducing activities such as induction of Treg cells, as well as other 
anti-inflammatory activities to include increased production of IL-22 (178). Several 
65 
 
studies, both in vivo and in vitro, have demonstrated that SCFA inhibit of histone 
deacetylases (HDACs), which results in many cases in the inactivation of nuclear factor-
κB (NF-κB) and downregulation of a number of pro-inflammatory cytokines, like tumor 
necrosis factor (TNF) (179, 180). In addition, increased SCFA could enhance the 
differentiation of peripheral Treg populations through HDAC9 inhibition, and 
consequently attenuation of colitis in mice (181). Gallausiaux et al. also show butyrate 
produced by gut commensal bacteria influence the proportion and activation of anti-
inflammatory regulatory T cells (Treg) (182).  Given this information, the increase in 
SCFAs like butyrate after TCDD exposure could explain some of the mechanisms which 
drive the immune suppression of this environmental pollutant. However, we found that 
direct administration of butyrate into ABX mice failed to induce MDSCs.   
 Mammalian cells, including immune cells, require the essential amino acid 
cysteine for protein synthesis and proliferation (183, 184). Cysteine is generated by cells 
through two distinct pathways. One involves reducing intracellular disulfide-bonded 
cystine which is imported through plasma membrane transporter Xc- to form cysteine, 
which is eventually exported through the plasma membrane ASC transporter. Another 
pathway involves converting intracellular methionine to cysteine if the cells synthesize  
cystathionase enzyme. T cells does not express Xc-
 
 and ASC however, and thus, they 
depend on antigen presenting cells (APCs) such as macrophage and dendritic cells to 
obtain cysteine (185-189).  MDSCs sequester cystine and do not export cysteine because 
they express only Xc-. Therefore, a large number of MDSCs in the microenvironment 
creates competition for cysteine between MDSCs and other immune cells, which can lead 
to reduction in cysteine levels, causing the suppression of T cell proliferation (120). In 
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the current report, TCDD reduced cysteine and methionine metabolism as evidenced 
through examination by PICRUSt, and these results were validated showing cysteine 
levels in the peritoneal cavity and colon exudates were decreased after TCDD exposure. 
The reason behind cysteine reduction after TCDD exposure could be attributed to 
sequestering by MDSCs, or it could also be attributed to an increase in bacteria, such as 
Lactobacillus, which use cysteine as a sulfur source to grow (190). It was thus interesting 
that when cysteine was provided in culture, it reversed the suppression of T cell 
proliferation mediated by MDSCs.   
 CXCR2 was shown to play a critical role in the induction of MDSCs. CXCR2 has 
been shown to play a critical role in MDSC migration to endometrial lesions through 
interactions with CXCL1, 2, and 5 (123).   The fact that blocking CXCR2 reduced 
MDSCs significantly both in the  colon and peritoneal cavity of TCDD-treated mice, 
confirmed the important role played by CXCR2 in inducing MDSCs in the colon.  In an 
earlier study, we noted that TCDD can induce CXCR2 in naïve mice because it expresses 
several DREs on its promoter .  Thus, AhR activation by TCDD involving DREs on 
CXCR2 gene promoter may help induce CXCR2 which in turn triggers MDSCs.   
In summary, the current report provides evidence that TCDD causes a shift in the resident 
gut microbiome, particularly through increasing Lactobacillus and decreasing Sutterella 
abundances. FMT experiments confirmed that TCDD-mediated changes in the gut 
microbiome altered the immune system, specifically by increasing the MDSCs in a 
CXCR2-dependent manner, which resulted in decreased cysteine levels. Such events may 
promote an immunosuppressive response, thus providing evidence that AhR activation by 
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Figure 3.1: TCDD treatment alters microbiome composition. C57BL/6 mice were 
treated with TCDD (10 µg/kg) or vehicle and 3 days later, feces were collected for 16S 
rRNA sequencing. (A) Rarefaction curves depicting alpha diversity within groups (Chao1 
index) of naïve (n=7), vehicle (n=6) and TCDD-treatment groups (n=6) are shown. (B) 
Three-dimensional principle coordinate analysis (PCoA) based on the unweighted 
UniFrac distance of all samples for three groups, naïve, vehicle and TCDD. (C) LeFSE-
generated cladogram for OTUs showing the phylum, class, order, family, genus and 
species from the outer to inner swirl, respectively. Red indicates enrichment in taxa in 
samples from naïve group, blue from vehicle group, and green from TCDD group. (D) 
LeFSE-generated LDA scores for differentially expressed taxa.  The threshold of LDA 
score was set to 3.5. (E) Percentage of OTUs of significantly-altered bacteria at the genus 
level. (F-G) q-PCR validation with primers for Lactobacillus (F) Sutterella and bacteria. 
(H) Concentration of butyric acid and acetic acid produced by the microbiota in the fecal 
contents. Bar graphs consists of vertical bars representing mean ± SEM.  One-way 
analysis of variance (ANOVA) with Tukey’s multiple comparisons test was used to 




Figure 3.2: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data 




Figure 3.3: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data 





Figure 3.4: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data 




Figure 3.5: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data 




Figure 3.6: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data 
depicting relative OTU abundance at the genus level. 
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Figure 3.7: Bacterial depletion in ABX mice. Naïve mice were treated with a cocktail  
of antibiotics for 3 weeks prior to FMT experiments. (A) UV agarose gel electrophoresis 
image of genomic DNA in naïve WT and ABX mice showing PCR expression of 
Eubacteria. (B) Relative normalized expression of Eubacteria in WT Naïve or ABX mice 
using qRT-PCR (C) UV images of culture plates with swabs from fecal samples from 




Figure 3.8: Effect of fecal microbiota transplantation on MDSCs and MDSC subset 
induction. Normal mice received Vehicle or TCDD and were analyzed for MDSCs or 
MDSC subsets in the peritoneal cavity (upper panels A, C, and panels B,D). Expression 
of CD11b and Gr-1 was used for MDSCs and CD11b and LY6C or LY6G for monocytic 
and granulocytic MDSCS, respectively. Also, ABX mice received feces from colon from 
vehicle (VFMT+ABX) or TCDD-treated mice (TFMT+ABX). And peritoneal cells were 
stained for MDSCs or subsets (lower panels A,C and panels B, E).  Panels A and C show 
percentages of MDSCs while panels B, D, E show absolute number of MDSCs. Vertical 






Figure 3.9: Effect of TCDD or FMT transfer into ABX mice on MDSC induction in 
ABX mice. These experiments were carried out as described in Fig 2 legend. ABX mice 
were administered TCDD alone, sodium butyrate alone, FMT from vehicle-treated 
(VFMT) or TCDD-treated (TFMT) donor mice. Peritoneal cavity fluid was collected and 
stained for CD11b Gr-1 for MDSCs and CD11b LY6C or LY6G for monocytic and 
granulocytic, respectively. (A) Representative flow plots of MDSCs (top) and MDSC 
subsets (bottom) in the ABX-treated mice given Butyrate, TCDD, VFMTs, and TFMT. 
(B-D) Total percentage of MDSCs and MDSC subsets in the ABX-treated mice given 
Butyrate, TCDD, and FMTs. Bar graphs consists of vertical bars representing 
mean ± SEM.  One-way analysis of variance (ANOVA) with Tukey’s multiple 




Figure 3.10: Fecal transplantation from TCDD-treated mice to ABX mice leads to 
induction of Tregs. FMT was performed as described in Fig 2 legend.  Cells from 
spleens of VFMT or TFMT recipient mice were processed to stain stained for T cell 
markers.  (A) Representative flow plot (CD4+CD3+) in spleen cells of ABX recipient 
mice following FMT from vehicle (VFMT) or TCDD (TFMT) donors. (B) Total cell 
number (CD4+CD3+) in spleen cells of ABX recipient mice following FMT from vehicle 
(VFMT) or TCDD (TFMT) donors. (C) Representative flow plot of Tregs 
(CD4+FoxP3+). (D) Percentage of Tregs from multiple experiments. Vertical bars 
represent mean ± SEM. Student’s t test was used for compression between the two groups 




Figure 3.11: Role of cysteine in TCDD-mediated immunomodulation.  C57BL/6 mice 
were treated with TCDD (10 µg/kg) or vehicle and feces were collected for 16S rRNA 
sequencing. (A) PICRUSt data from Nephele depicting KEGG pathways altered in 
vehicle (n=6), and TCDD (n=6) gut microbiome.  (B) Percent OTUs attributed to 
cysteine and methionine metabolism. (C) qPCR quantification of ASC (alanine-serine-
cysteine transporter) neutral amino acid transporter, XCT (light chain of antiporter Xc-) 
and 4F2 (heavy chain of antiporter Xc-) chains; CTH (cystathionase) . MDSCs were 
selected by PE selection kit from peritoneal fluid of vehicle or TCDD-treated groups. (D) 
Cysteine  level quantification in peritoneal and colon exudate in vehicle or TCDD mice. 
(E) Representative 3H-thymidine incorporation assay for T-cell proliferation in media 
deficient in cysteine or with cysteine. Student’s t test and one-way analysis of variance 





Figure 3.12: Role of CXCR2 in TCDD-mediated induction of MDSCs. Colon samples 
from three groups: Vehicle, TCDD, and TCDD with CXCR2 antagonist Sch527123 were 
fixed with 4% paraformaldehyde in PBS overnight and then sectioned to 5 µm thickness 
on coated slides. Slides were incubated with antibody detection of Gr-1, CD11b, and 
Arg1 (A) CD11b Gr-1 fluorescence staining in colon. Colon section from three groups 
were stained with CD11b (green) and Gr-1(red) to detect MDSCs. (B) Arg1 fluorescence 
staining (green) to quantify Arg1 expression in colon of three groups. (C-D) Statistical 
analysis of CD11b Gr-1 and Arg1 expression in colon sections of three groups as 
measured in CTCF using image J software. (E) Representative flow plots of MDSCs in 
peritoneal fluid in vehicle, TCDD and TCDD with CXCR2 antagonist Sch527123. (F) 
Absolute numbers of MDSCs in peritoneal fluid in vehicle, TCDD and TCDD with 
CXCR2 antagonist Sch527123. One-way analysis of variance (ANOVA) and Tukey’s 
multiple comparisons test were used to compare between the groups. *p < 0.05; 




RESVERATROL-MEDIATED ATTENUATION OF TCDD-INDUCED MDSCS 
MOBILIZATION, DIFFERENTIATION AND SUPPRESSIVE FUNCTION  
 
4.1 ABSTRACT 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of 
cells that are defined by their myeloid origin, immature state, and ability to potently 
suppress immune response. Murine MDSCs are characterized by the expression of 
CD11b and   G-r1 cell markers and can be subdivided into two groups, monocytic and 
polymorphonuclear MDSCs based on the expression of Ly6C and Ly6G molecules. 
Previously, we found that 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), an Ahr high 
affinity binding ligand induces MDSCs and MDSC subset migration from bone marrow 
to peritoneal cavity. In the current study, we demonstrate that oral administration of 
3,5,4′-trihydroxy-trans-stilbene (Resveratrol, RSV) reduced the number of MDSCs in the 
peritoneal cavity and immobilized these cells in the bone marrow. Cell bioenergetic 
profile and suppressive function of MDSCs were evaluated in TCDD group with and 
without RSV treatment. MDSCs with RSV treatment exhibited low glycolytic proton 
efflux rate (PER) which negatively affected their suppressive functions against T-cell 
proliferation. Furthermore, we found by flow cytometry strategy that both TCDD and 
RSV play a significant role in monocyte and dendritic cell differentiation and Class II-
MHC expression.  In summary, our data revealed that RSV can prevent MDSCs 




Myeloid cells have a significant role in the innate immune response via several 
functions including the phagocytosis of pathogens (by macrophages), processing and 
presentation of antigens (by dendritic cells (DCs), stimulation of an inflammatory 
response (by neutrophils), and promotion of wound healing (by platelets) (191). 
Monocytes that derive from bone marrow, migrate to tissue and differentiate into 
macrophage and DC. Immature myeloid cells that do not have immunosuppressive 
activity are present constantly in health  individuals (192). However, the accumulation of 
undifferentiated myeloid derived suppresser cells (MDSCs) which have high suppressive 
activity against T cells is one of  the reasons that contribute to development of cancers, 
chronic infections, and autoimmune diseases (193-195). MDSCs consist of two large 







cells with high side scatter and monocytic MDSCs (M-






 cells with low side scatter (22). Both 
groups have different phenotypes and suppressive functions (196).  
Macrophage in the peritoneal cavity (PerC) have been  divided according to their 





 and express low levels of MHC class II (MHCII) and small peritoneal 




and express high levels of MHCII 
(197).  
 Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that 
cross talks with environmental, dietary, microbial and metabolic signals to control 
complex transcriptional programs in a ligand-specific, cell-type-specific and context-
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specific manner (198). AhR has important role in regulation of innate and adaptive 
immunity because it is expressed by numerous of immune cells (199). Previous studies 
from our lab showed that AhR activation caused thymus atrophy by  upregulation of 
genes including Fas, LIGHT, and CD30 that enhance negative selection and  lead to 
thymic atrophy (85), or by regulation of  FasL and NF-kappaB in stromal cells, which in 
turn plays a critical role in initiating apoptosis in thymic T cells (86). AhR activation also 
reversed Th17/Treg differentiation  for Treg favor in colitis animals model (50). 
Expression of  hypersensitivity to LPS-induced septic shock with increasing mortality 
rate in AhR deficient mice is an indicator of the critical role of AhR in immune system 
homeostasis (200).  There are also studies that showed how Ahr activation can impair the 
differentiation of human monocytes to macrophages or dendritic cells (201, 202).  Also, 





 mice to subtoxic doses of BaP showed that AhR-induced gene 
regulation is crucial for homeostasis of pro- and anti-inflammatory cytokines during 
macrophage activation (203).  
  A broad range of ligands with agonistic and antagonistic properties and with 
various affinity binding sites to AhR have been investigated for their role in 
immunomodulation. These ligands could be exogenous such as indole-3-carbinol and 
resveratrol or toxic environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), or could be endogenous ligands such as kynurenine and 6 Formylindolo[3,2-
b]carbazole (5). Interestingly, AhR activation influences many and different aspects of 
immunological function, for example, TCDD and FICZ are high affinity AhR ligands, 
however TCDD induce anti-inflammatory molecules/cytokines such as FOXP3 and IL-10 
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that suppressed experimental autoimmune encephalomyelitis while FICZ induces pro-
inflammatory cytokine IL-17 and increases the severity of experimental autoimmune 
encephalomyelitis in mice (89).  
From previous work, we found TCDD (10µg/kg) induced rapid and massive 
mobilization of MDSCs and MDSCs subsets such as monocytic and polymorphonuclear 
MDSCs from bone marrow to peritoneal cavity. In the present study, we observed that 
resveratrol ameliorated immunotoxicity effect of TCDD and attenuated the proportion of 
MDSCs and MDSCs subset in the peritoneal cavity. Also, we found both AhR agonist 
and antagonists had significant influence on monocyte differentiation in the peritoneal 
cavity post treatment.   
4.3 MATERIALS AND METHODS 
Experimental Animals: 
Female mice C57BL/6 mice (6-8) weeks old were purchased from Jackson 
laboratory, USA. All mice were housed in specific pathogen-free condition at the 
AAALAC-accredited University of South Carolina, School of Medicine, Animal 
Resource Facility. All experiments performed using mice in this manuscript were 
approved by the Institutional Animal Care and Use Committee (IACUC), University of 
South Carolina.   
Chemicals and reagents: 
TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences & 
Technology, Texas A&M Health Sciences Center, College Station, Texas). Resveratrol 
(RSV) was from Sigma-Aldrich (St. Louis, MO).  Culture medium reagents (RPMI 1640, 
Penicillin-Streptomycin, HEPES, L-Glutamine, FBS, and PBS) were purchased from 
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Invitrogen Life Technologies (Carlsbad, CA). The following antibodies were used for 
surface markers staining were purchased from BioLegend (San Diego, CA-USA): Alexa 
Fluor 700-conjugated anti-CD11b, BV510-conjugated-Gr-1, Alexa Fluor 488-conjugated 
anti-Ly6C, BV785-conjugated anti-Ly6G, BV421-conjugated anti-MHCII, and BV605 or 
PE-conjugated anti-CD11c. Fc Blocker reagent was procured from BD Biosciences (San 
Diego, USA). PE Positive Selection Kits were purchased from Stem cells Technologies 
(Vancouver, BC, Canada). XFp glycolytic rate assay kit and XFP cell mito stress test kit 
were purchased from Agilent Technologies.  
Animals treatment and flow cytometry staining 
C57BL6 mice (n=5) were given 50 mg/kg orally RSV and the following day, they 
were injected with 10 µg/kg TCDD and 90 min later they given a second dose of RSV.  
Next day, they sacrificed and peritoneal exudates harvested and stained for flow 
cytometry. Flow cytometry analysis was performed using BD FACs Celeste and FlowJo 
software from ThermoFisher Scientific. 
Flow cytometry to evaluate immune cell phenotypes  
 Cells were harvested from peritoneal cavity of naïve, RSV, TCDD, and 


















) MDSCs as described by us previously (103). 
According to flow cytometer strategy of gating (204), we stained with CD11b and F4/80 

























). Also, MHCII 
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expression detected in LPM, SPM, MDSCs, and nonNCorDC. Flow cytometry analysis 
was performed using BD FACs Celeste and FlowJo software from ThermoFisher 
Scientific.   
 Purification of MDSCs 
MDSCs were purified from  peritoneal exudates of RSV, TCDD, and 
RSV+TCDD mice, as described previously (31). In brief, peritoneal exudates were 
collected and labeled with PE-conjugated Gr-1 antibody. PE-selection kit from Stem 
Cells Technologies was used for selection by following the protocol from company. After 
purification, flow cytometry (BD FACScelesta) was used to assess the purity of MDSCs.  
Effect of MDSCs from TCDD or RSV+TCDD on T-cell proliferation in vitro.    
To examine the suppressive effect of MDSCs on T-cell proliferation, splenocytes 
(5x10
5
) from C57BL/6 naïve mice were cultured in the presence of Con-A (2µg/ml) 
together with  1:0.5 ratios of  MDSCs from TCDD or RSV+TCDD for 24 hrs, as 
described (104). [3H]thymidine (1µCi/well) was added to the cell cultures and after 18 
hrs, radioactivity was measured using a liquid-scintillation counter (MicroBeta Trilux; 
PerkinElmer Life and Analytical Sciences). 
 Measuring Glycolytic Rate 
Proton efflux rate (PER) was measured in 2×10
5
 purified MDSCs from peritoneal 
cavity of RSV, TCDD, and RSV+TCDD-treated mice using XF Extracellular Flux 
Analyzer (Seahorse Bioscience). MDSCs were plated in XF cell culture plate coated with 
15 μg CellTak in phenol red-free Base Medium enriched with 2 mM glutamine, 10 mM 
glucose, 1 mM pyruvate, and 5 mM HEPES as initial conditions. Cells monitored under 
stressed conditions and in response to 0.5 µM Rotenone plus Antimycin A (Rot/AA) and 
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50 mM 2-Deoxy-D-glucose (2-DG). PER quantified by Seahorse Bioscience XFp 
Extracellular Flux Analyzer (Agilent Technologies).  
4.4 RESULTS           
RSV attenuated MDSCs mobilization from bone marrow to peritoneal cavity. 
From previous work, we found that TCDD caused massive mobilization of 
MDSCs to the peritoneal exudate.  While TCDD and RSV both are AhR ligands, TCDD 
has high binding affinity towards AhR (205) while RSV binds to AhR with low affinity 
(92) Moreover studies from our lab have previously shown that based on the dose of 
RSV, it can also act as an antagonist for AhR (205).  Thus, in the current study, we 
investigated if RSV would reverse the ability of TCDD to induce MDSCs.  We observed 
that the proportion and absolute numbers of MDSCs in bone marrow of TCDD-treated 
mice decreased significantly within 16 hours of exposure while we noted significant 
increase in MDSCs in the peritoneal cavity (Fig 4.1A-D).  Interestingly, RSV+TCDD 
treated groups showed reversal of TCDD effects inasmuch as there were more numbers 
of MDSCs in the bone marrow while there was less MDSCs induced in the peritoneal 
cavity (Fig 4.1A-D).  A similar trend was seen at 24 hours in the peritoneal cavity (Fig 
4.1E-F).   
RSV impaired glycolytic rate and suppressive function of TCDD-induced MDSCs.  
Next, we tested the Proton Efflux Rate (PER) in MDSCs that were induced by 
TCDD with or without RSV. Interstitially, we found that RSV impaired PER in MDSCs 
cells compared to MDSCs treated with TCDD (Fig 4.2A). Also, all PER parameters 
including basal glycolysis, percentage of PER, and compensatory glycolysis were 
reduced  in RSV+TCDD group when compared to TCDD (Fig 4.2B). When we tested the 
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suppressive function of MDSCs, we found that MDSCs from TCDD treated mice were 
highly immunosuppressive while MDSCs from RSV+TCDD mice were less 
immunosuppressive when compared to TCDD-treated mice (Fig 4.2C).  Together, these 
data demonstrated that RSV is capable to reducing the migration, and function of TCDD-
induced MDSCs.  
RSV and TCDD, AhR ligands influence in peritoneal cavity monocytes 
differentiation 
 
We also examined if Ahr activation by TCDD influences in the differentiation of 
monocytes in murine peritoneal cavity.  According to flow cytometer strategy of gating 
(204), we found that the proportion of CD11b
+
 monocytes reduced significantly in TCDD 





, were seen in all experimental groups at low levels. However, there was a 
significant difference between naïve and RSV and between TCDD and RSV+TCDD 
groups.  Peritoneal cells from RSV expressed higher percentages of large peritoneal 




when compared to cells in TCDD and 
RSV+TCDD (Fig 4.3B,K). MDSCs as well as PMN-MDSCs and M-MDSCs increased 










) exhibited high level expression in TCDD, while showing 




 were in high 
proportion in naïve mice and decreased dramatically in TCDD while RSV+TCDD 
showed an increase when compared to TCDD (Fig 4.3E,M).  MHCII was expressed at 
higher levels in SPM, while it’s expression in LPM was lower and increased gradually 
with TCDD and RSV+TCDD. Like SPM, nonDCorNC expressed high MHCII (Fig 
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4.3F,I,M), while in contrast, the expression of MHCII was lacking in MDSCs. However, 
MDSCs in RSV treated group exhibited higher levels of MHCII expression (Fig 4.3G,N), 
demonstrating a virous effect of Ahr ligand on differentiation of the peritoneal cavity 
monocytes.      
4.5 DISSUCSION   
TCDD and other aryl hydrocarbon receptor (AhR) xenobiotic ligands, such as 
polycyclic aromatic hydrocarbons (PAHs), are environmental toxicants generated by the 
chemical industry. They are present in air pollution from industrial furnace gas and 
burning processes. Many AhR ligands, especially the halogenated have long biological 
half-life in body fat which keep increasing with time (206). Resveratrol a polyphenolic 
natural compound has been extensively studied for its therapeutic benefits against a wide 
array of diseases including cancer, cardiovascular, neurological and inflammatory 
diseases (62, 66, 81, 82, 122). In the current study, we investigated other protective role 
of RSV against immunotoxicity effect of TCDD. We found that RSV attenuated the 
massive mobilization of MDSCs from bone marrow to peritoneal cavity in TCDD 
treatment (Fig 4.1). Both TCDD and RSV are AhR agonists and binding to different 
residues binding domain (AhRLBD) in AhR. However, some of the residues in AhR 
LBD contribute significantly to binding with the ligands (92) that lead to create a kind of  
competition between the ligands on binding site. Also, our previous studies have shown 
that RSV can both act as an agonist and antagonist based on the dose (207) .   
   Tumor-infiltrating MDSC (T-MDSC) increase fatty acid uptake and activated 
fatty acid oxidation (FAO) that is accompanied by an increase in oxygen consumption 
rate (208). Thus, FAO inhibition alone significantly delayed tumor growth in a T-cell-
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dependent manner and enhanced the antitumor effect of adoptive T-cell therapy (26). In 
the present study, we observed that RSV impaired protein efflux rate during glycolysis 
that was seen at high levels with TCDD treatment (Fig 4.2A-B). Inhibition glycolysis by 
RSV potentially had a reduced effect on suppressive function of MDSCs in T-cells 
proliferation (Fig 4.2C).   
AhR is expressed at high levels in monocytes, macrophage, Th17, ILC3 and DC, 
inducible in B cells and NK, and low levels in Th1, Th2, ILC1and2, and granulocytes  
(209). Because AhR is expressed highly in monocytes, activation AhR by their agonists 
perhaps control monocyte differentiation.  A couple studies addressed this question and 
found that activation of AhR impeded the differentiation of myeloid cells to macrophage 
(202, 203). In the present study, we found that TCDD impaired the proportion of 
peritoneal macrophage subset, LPM and SPM. However, LPM with RSV treatment 
exhibited higher percentages demonstrating that both ligands have differential effects on 
LPM differentiation.  Induction of LMP and SMP by RSV can be one of reasons behand 
reduced MDSCs population in TCDD with RSV (Fig 4.3B,K). Also, increase of DC 
expression with RSV+TCDD may be because DC express highly level of AhR that lead 
to increase the proportion of these cells with two ligands. NonDCorNC show a high 
proportion in naïve mice when compared to treatments, giving evidence for critical roles 
of both TCDD and RSV in monocytes differentiation (Fig 4.3E,M). RSV also caused a 
decrease in MDSC subsets, PMN-MDSCs and M-MDSCs when compared to TCDD (Fig 
4.3C,L) which correlated with a decrease in MDSC induction as well. SPM expresses 
high levels of MHCII, which is not expressed on LPM  (204). Similarly, we found SPM 
in all experimental groups expressed MHCII, however the expression of MHCII in LPM 
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increased with RSV+TCDD, which may explains why RSV treatment reduces the 
suppressive activity of MDSCs (Fig 4.3F,I,M). MDSCs normally  lack  MHCII 
expression  and it can be  distinguished from monocytes by this feature (196). We 
observed that MHCII expression in MDSCs in TCDD was negligible, however MDSCs 
with RSV showed slight increase in MHCII (Fig 4.3G,N) that may have also caused  
reversal of suppressive functions (Fig 2).   
In summary, the current study demonstrates that RSV can neutralize the 
immunotoxicity of TCDD.  Specifically, RSV decreased the induction of MDSCs by 
TCDD.  Also, RSV reversed the immunosuppressive functions of TCDD -induced 
MDSCs against T cell proliferation.  Lastly, TCDD also altered the differentiation of 
dendritic cells and monocytes and RSV also interfered in this process.  Clearly additional 
studies are necessary to understand if the effect of TCDD on monocytes and DCs results 




Figure 4.1: Resveratrol (RSV) attenuated MDSCs mobilization from bone marrow 
to the peritoneal cavity. Mice were given prior 50 mg/kg orally RSV, next day they 
injected with 10 µg/kg TCDD and 90 min later they given a second dose of RSV.  Next 
day they sacrificed and peritoneal exudates harvested to stain with CD11b Gr-1 to 
identify MDSCs and LY6C and LY6G to identify monocytic M-MDSCs and 
polymorphonuclear PMN-MDSCs respectively. (A) Representative plots from flowjo 
software analysis of flow cytometry data showing MDSCs proportion in BM in 0 hr and 
after 16 hrs. (B) Representative pseudocolor plots showing MDSCs proportion in 
peritoneal exudate in 0 hr and 16 hrs later. (C) Absolute number of bon marrow-MDSCs 
(BM-MDSCs) in 0 hr and after 16 hrs. (D) Absolute number of peritoneal cavity-MDSCs 
(PC-MDSCs) in 0 hr and 16 hrs later. (E,F) Percentage and absolute number of MDSCs 
in peritoneal cavity in 24 hrs later. Vertical bars represent mean ± SEM. Student’s t test 




Figure 4.2: RSV impaired protein efflux rate (PER) and immunosuppressive 
function in MDSCs. MDSCs were purified from the peritoneal cavity of RSV, TCDD, 
and RSV+TCDD mice as described in material and methods and utilized for PER and 
3H-thymidine assays. (A) Proton efflux rate in peritoneal MDSCs in three experimental 
groups. (B) Glycolysis parameters quantification including glycolysis, percentage of 
PER, and compensatory glycolysis in RSV, TCDD, and RSV+TCDD. (C) Purified 
peritoneal MDSCs from TCDD and RSV+TCDD were incubated with spleen cells 
activated with ConA at 1:0.5. T cell proliferation was assessed by 3H-thymidine 





Figure 4.3: Flow gating strategy to identify immune cells in the peritoneal cavity. 
Based on surface molecules, peritoneal fluid cells in naïve, RSV, TCDD, and 
RSV+TCDD stained for. (A) Single cells selection by gating on FSC-H and FSC-A. (B) 









cells with high side 
scatter, small peritoneal macrophage (SPM) can be defined as CD11binF4/80in with 




 gated on single cells. (D) 
Polymorphonuclear (PMN) and Monocytic (M) MDSCs gated on CD11b. (E) Gr-1 and 













NonNCorDC. (F,I) MHCII expression on LPM, SPM, and 
NonNCorDC. (G) MHCII expression on MDSCs. (K) Percentage of Monocytes, LPM, 
SPM, and MDSCs. (L) Percentage of MDSCs subset population. (M) DC, NC and 
NonNCorDC proportion. (N) MHCII expression in LPM, SPM, NonNCorDC and 





SUMMARY AND CONCLUSION 
 The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that 
acts as biological sensor by initiating gene expression programs in response to 
endogenous and exogenous signals. One of the contaminant exogenous ligands that has 
high affinity binding to AhR with immunotoxic and carcinogenic properties is TCDD 
(2,3,7,8-Tetrachlorodibenzo-p-dioxin).  The data presented in this dissertation showed 
that TCDD caused significant immunomodulation and alterations in gut microbiota.  On 
the other hand, resveratrol, a natural polyphenolic compound with known agonistic and 
antagonistic activity attenuated immunomodulatory effects of TCDD.         
 TCDD induced immunomodulation included massive mobilization of MDSCs 
from bone marrow to peritoneal cavity that was associated with increases in several 
chemokines and their receptors. TCDD-induced MDSCs were highly immunosuppressive 
as demonstrated using in vitro and adoptive transfer experiments which correlated with 
increase in bioenergetic profile of these cells. TCDD also caused epigenetic modification 
in MDSCs that was accompanied with down-regulation in the expression of miR-150-5p 
and miR-543-3p which led to increase in the expression of target genes including IL-10, 
PIM1, ARG2, STAT3, and CCL11 and chemokines receptors CCR3, CCR5, and 
CXCR2. Upregulation of these anti-inflammatory genes, chemokines, and their receptors 
played a major role in the migration, expansion and function of MDSCs. 
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The influence of TCDD was not limited only to the immune system, TCDD also 
caused shift in the resident gut microbiome, particularly through increasing Lactobacillus 
and decreasing Sutterella abundances.  FMT experiments confirmed that TCDD-mediated 
changes in the gut microbiome altered the immune system, specifically by increasing the 
MDSCs in a CXCR2-dependent manner, which resulted in decreased cysteine levels.  
 Data presented in the current work also provide evidence for neutralizing the 
immunotoxicity of TCDD. Resveratrol, a natural compound, was found to reduce 
significantly the massive MDSC mobilization to the peritoneal cavity and reversed their 
suppressive function.  
Together, these studies demonstrate for the first time how AhR activation by 
ligands can serve as a double-edged sword on one hand inducing MDSCs that may be 
beneficial to treat inflammatory and autoimmune diseases while on the other hand 
promoting cancer.  This may explain how some dietary AhR ligands may help suppress 
inflammation in the colon and systemically, while some environmental toxicants such as 
TCDD and methyl cholanthrene may induce cancer.  Our studies form the basis for 
further investigations into such mechanisms which may help develop novel therapies to 
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